Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or epileptic seizures
Novel Kv7 potassium channel openers targeting Kv7.2, Kv7.3, and Kv7.4 channels offer a promising treatment for epilepsy by modulating neuronal excitability and reducing seizure activity, addressing the limitations of current therapies.
Patent Information
- Application Number
- JP2022506568
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-02
- Filing Date
- 2020-07-30
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2040-07-30
AI Technical Summary
Current treatments for epilepsy and epileptic seizures often lack efficacy and are associated with undesirable side effects, highlighting the need for new therapies that can effectively manage these conditions.
Development of novel compounds that act as Kv7 potassium channel openers, specifically targeting Kv7.2, Kv7.3, Kv7.4, and Kv7.5 channels, to modulate neuronal excitability and reduce seizure activity.
The novel compounds demonstrate anticonvulsant effects in rat models, potentially providing a more effective treatment for various types of epilepsy and epileptic seizures with reduced side effects.
Smart Images

Figure 0007591036000185 
Figure 0007591036000001 
Figure 0007591036000002
Abstract
Description
[Technical field]
[0001] The present invention relates to the use of novel compounds that activate Kv7 potassium channels in the treatment of epilepsy or epileptic seizures. [Background technology]
[0002] Voltage-gated potassium (Kv) channels transport potassium ions (Kv) across the cell membrane in response to changes in membrane potential. + ) and thereby control the excitability of cells by modulating (increasing or decreasing) the electrical activity of the cells. Functional Kv channels exist as multimeric structures formed by the association of four α and four β subunits. The α subunits contain six transmembrane domains, a pore-forming loop, and a voltage sensor, arranged symmetrically around a central pore. The β or auxiliary subunits can interact with the α subunits to modify the properties of the channel complex, including but not limited to changes in the electrophysiological or biophysical properties of the channel, expression levels, or expression patterns.
[0003] Nine families of Kv channel α subunits have been identified, designated Kv1-Kv9, and there is therefore a great deal of diversity in Kv channel function resulting from the large number of subfamilies, the formation of both homologous and heterologous subunits within a subfamily, and the additive effects of association with β subunits (Christie, 25 Clinical and Experimental Pharmacology and Physiology, 1995, 22, 944-951).
[0004] The Kv7 channel family consists of at least five members, including one or more of the mammalian channels Kv7.1, Kv7.2, Kv7.3, Kv7.4, Kv7.5, and any mammalian or non-mammalian equivalents or variants (including splice variants) thereof. The members of this family are alternatively referred to by the gene names KCNQ1, KCNQ2, KCNQ3, KCNQ4, and KCNQ5, respectively (Dalby-Brown, et al., Current Topics in Medicinal Chemistry, 2006, 6, 9991023).
[0005] As mentioned above, the Kv7 potassium channel in neurons plays a role in controlling neuronal excitability. Kv7 channels, particularly the Kv7.2 / Kv7.3 heterodimer, underlie the M-current (Wang et al Science. 1998 Dec 4; 282(5395):1890-3). The M-current has a characteristic time- and voltage-dependence that results in the stabilization of the membrane potential in response to multiple excitatory stimuli.
[0006] Thus, the M-current is involved in the control of neuronal excitability (Delmas & Brown, Nature, 2005, 6, 850-862). The M-current is a non-inactivating potassium current found in many neuronal cell types. In each cell type, it dominates the control of membrane excitability by being the only sustained current within the range of action potential initiation (Marrion, Annual Review Physiology 1997, 59, 483-504).
[0007] Retigabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethyl ester) is a compound that binds to the Kv7 potassium channel (Wuttke, et al., Molecular Pharmacology, 2005, 67, 1009-1017). Retigabine binds to the Kv7 channel in neurons. + The pharmacology of this induced current is determined by the Kv7.2 / 3 K +This is consistent with the published pharmacology of M-channels, which correlates with channel heteromultimers, suggesting that activation of Kv7.2 / 3 channels is responsible for at least part of the anticonvulsant effects of this drug (Wickenden, et al., Molecular Pharmacology 2000,58,591-600; Gunthorpe et al. Epilepsy. 2012 Mar;53(3):412-24). Retigabine is effective in reducing the incidence of epileptic seizures in epilepsy patients (Bialer, et al., Epilepsy Research 2002,51,31-71). Retigabine has a broad spectrum and strong anticonvulsant effect. It is effective after oral and intraperitoneal administration in rats and mice in various anticonvulsant tests (Rostock, et al., Epilepsy Research 1996,23,211-223).
[0008] The five members of this family differ in their expression patterns: expression of Kv7.1 is restricted to the heart, peripheral epithelium, and smooth muscle, whereas expression of Kv7.2, Kv7.3, Kv7.4, and Kv7.5 appears to predominate in the nervous system, including the hippocampus, cerebral cortex, ventral tegmental area, and dorsal root ganglion neurons (see Greene & Hoshi, Cellular and Molecular Life Sciences, 2017, 74(3), 495-508 for review).
[0009] The KCNQ2 and KCNQ3 genes appear to be mutated in an inherited form of epilepsy known as benign familial neonatal convulsions (Rogawski, Trends in Neurosciences 2000, 23, 393-398). The proteins encoded by the KCNQ2 and KCNQ3 genes are localized in pyramidal neurons of the human cerebral cortex and hippocampus, areas of the brain associated with the generation and propagation of epileptic seizures (Cooper et al., Proceedings National Academy of Science USA 2000, 97, 4914-4919).
[0010] Furthermore, in addition to Kv7.2 mRNA, Kv7.3 and 5 mRNA are expressed in astrocytes and glial cells. Thus, Kv7.2, Kv7.3 and Kv7.5 channels may help regulate synaptic activity in the CNS and contribute to the neuroprotective effects of KCNQ channel openers (Noda, et al., Society for Neuroscience Abstracts 2003, 53.9), making them suitable for the treatment of neurodegenerative diseases, such as, but not limited to, Alzheimer's disease, Parkinson's disease and Huntington's disease.
[0011] Kv7.2 and Kv7.3 subunit mRNAs are found in brain regions associated with anxiety and emotional behaviors, such as depression and bipolar disorder, such as the hippocampus, ventral tegmental area, and amygdala (Saganich, et al. Journal of Neuroscience 2001,21,4609-4624; Friedman et al., Nat Commun. 2016;7:11671.), and retigabine has been reported to be effective in animal models of anxiety-like behavior (Korsgaard et al J Pharmacol Exp Ther. 2005 Jul;314(1):282-92. Epub 2005 Apr 6.). Therefore, Kv7 channels are suitable for the treatment of emotion-related disorders, including but not limited to bipolar depression, major depression, anxiety neurosis, suicide, anxiety attacks, and social phobia.
[0012] Kv7.2 / 3 channels have also been reported to be upregulated in models of neuropathic pain (Wickenden, et al., Society for Neuroscience Abstracts 2002, 454.7), and potassium channel modulators have been hypothesized to be effective in both neuropathic pain and epilepsy (Schroder, et al., Neuropharmacology 2001, 40, 888-898). In addition to their role in neuropathic pain, expression of Kv7.2-5 mRNA in the trigeminal ganglion and dorsal root ganglion, as well as the trigeminal nucleus caudalis, means that openers of these channels may also affect sensory processing in migraine (Goldstein, et al. Society for Neuroscience Abstracts 2003, 53.8). Taken together, this evidence indicates the relevance of KCNQ channel openers for the treatment of chronic pain and neuropathy-related disorders.
[0013] WO 07 / 90409 relates to the use of Kv7 channel openers for the treatment of schizophrenia. Kv7 channel openers are useful for modulating the function of the dopaminergic system (Friedman et al., Nat Commun. 2016; Scotty et al J Pharmacol Exp Ther. 2009 Mar;328(3):951-62.doi:10.1124 / jpet.108.146944.Epub 2008 Dec 19; Koyama et al., J Neurophysiol. 2006 Aug;96(2):535-43.Epub 2006 Jan 4; Li et al Br J Pharmacol. 2017 Dec;174(23):4277-4294.doi:10.1111 / bph.14026.Epub 2017 Oct 19.; Hansen et al J Pharmacol Exp Ther. 2006 Sep;318(3):1006-19.Epub 2006 Jun 14), which are suitable for treating mental disorders including but not limited to psychosis, mania, stress-related disorders, acute stress reaction, attention deficit hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder, impulsive disorders, personality disorder, schizophrenia-type disorder, aggression, autism spectrum disorder, etc. WO 01 / 96540 discloses the use of regulators of M-current formed by the expression of KCNQ2 and KCNQ3 genes for insomnia, and WO 01 / 092526 discloses that regulators of Kv7.5 can be used to treat sleep disorders. WO 09 / 015667 discloses the use of Kv7 openers in the treatment of sexual dysfunction.
[0014] Although patients suffering from the above diseases may have available treatment options, many of these options lack the desired efficacy and are associated with undesirable side effects. Thus, there is an unmet need for new therapies for treating epilepsy and seizures.
[0015] In an effort to identify new therapeutic approaches, the present inventors have identified a series of novel compounds of formula I that act as Kv7.2, Kv7.3, Kv7.4 and Kv7.5 channel openers as pharmaceuticals for the treatment of epilepsy, epileptic syndromes and conditions, and epileptic seizures. Summary of the Invention
[0016] The present invention relates to a compound of formula I for use in the treatment of epilepsy, an epilepsy syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure. [ka] (In the formula, R1 is selected from the group consisting of C1-C6 alkyl, CF3, CH2CF3, CF2CHF2, C3-C8 cycloalkyl, where the C3-C8 cycloalkyl may be substituted with one or two F, CHF2 or CF3, and R2 is H, C1-C6 alkyl or CF3; Or, R1 and R2 join to form a C3-C5 cycloalkyl optionally substituted with F, CHF2 or CF3; R3 is C1-C3 alkyl optionally substituted with F or CH2O-C 1~3 is alkyl, R4 is selected from the group consisting of OCF3, OCH2CF3, or OCHF2. or a pharma- ceutically acceptable salt thereof.
[0017] The present invention further relates to pharmaceutical compositions comprising a compound of the present invention and a pharma- ceutically acceptable carrier or excipient.
[0018] The present invention further relates to a method of treating a patient as described in the claims and embodiments, including treating a patient suffering from epilepsy, an epileptic syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure, comprising administering to the subject a therapeutically effective amount of a compound of the present invention. [Brief description of the drawings]
[0019] [Figure 1] Acute administration of (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide demonstrates anticonvulsant effects in the rat MEST assay. Oral administration of (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide to rats 30 min prior to testing significantly elevated the epileptic seizure threshold CC50 (i.e., the current applied to the animals (measured in mA) that produces tonic hindlimb extensor seizures in 50% of the animals) compared to vehicle at all doses tested (0.03-1 mg / kg). **<0.01, ***: p<0.001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] Detailed Description of the Invention According to an embodiment of the invention, R4 is OCF3 or OCHF2, and according to another embodiment, R2 is H or CH3.
[0021] In one embodiment, R1 is a C3-C4 cycloalkyl optionally substituted with one or two F, CHF2, or CF3.
[0022] According to a particular embodiment, R1 is t-butyl, R2 is H, and R4 is one of OCF3, OCH2CF3, or OCHF2.
[0023] According to another particular embodiment, R1 and R2 join to form a cyclobutyl optionally substituted with one or two F, and R4 is one of OCF3, OCH2CF3, or OCHF2.
[0024] According to a particular embodiment of the invention, the compound of the invention comprises (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (R)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-((trifluoromethyl)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (S)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)propanamide, (R)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(R)-hydroxy-4,4-dimethylpentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(S)-hydroxy-4,4-dimethylpentanamide, (S)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (R)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (S)-2-(1-hydroxycyclobutyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)acetamide, (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, 4,4,4-trifluoro-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(trifluoromethyl)butanamide, (R)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide, (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)butanamide, (R)-2-(1-hydroxycyclopentyl)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (R)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (S)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (S)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxyphenyl)ethyl)butanamide, and (R)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide or a pharma- ceutically acceptable salt of any of these compounds. is selected from the group consisting of:
[0025] Reference to a compound encompassed by the present invention includes racemic mixtures of the compound, optical isomers of the compound to which it is related, and polymorphic and amorphous forms of the compound of the present invention, as well as tautomeric forms of the compound to which it is related. Additionally, the compounds of the present invention may optionally exist in unsolvated and solvated forms with pharma- ceutically acceptable solvents such as water, ethanol, etc. Both solvated and unsolvated forms of the compounds are encompassed by the present invention.
[0026] The compounds of the invention can be present in a pharmaceutical composition comprising the compound and a pharma- ceutically acceptable excipient or carrier.
[0027] In another embodiment, the present invention relates to a method of treating a patient in need thereof suffering from epilepsy, an epileptic syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure, comprising administering to the subject a therapeutically effective amount of a compound of the present invention.
[0028] In yet another embodiment, the present invention provides a method for treating focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g., severe myoclonic epilepsy of infancy, epilepsy with persistent spike-and-wave during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy). The present invention relates to a method for treating a patient in need thereof suffering from epilepsy due to Ohtahara syndrome, or epileptic seizures associated with stress, hormonal changes, drugs (e.g., amphetamines or cocaine), alcohol, infection, or metabolic disorders (e.g., hyponatremia), or for use in treating epileptic symptoms as part of a neurodegenerative disorder, such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc., comprising administering to a subject a therapeutically effective amount of a compound of the present invention.
[0029] Use of the compounds of the invention is for the treatment of epilepsy, including use in the treatment of focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epileptic syndromes (e.g. severe myoclonic epilepsy of infancy, persistent spike-and-wave epilepsy during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy-Ohtahara syndrome), or epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders (e.g. hyponatremia), or for use in epileptic conditions as part of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc.
[0030] Compounds for use in accordance with the present invention may be used to treat focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g. severe myoclonic epilepsy of infancy, epilepsy with continuous spike-and-wave during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy). for the treatment of epilepsy, including for use in the treatment of epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders (e.g. hyponatremia), or in epileptic conditions as part of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc.
[0031] In another embodiment, the compounds of the invention are useful in the treatment of focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g., severe myoclonic epilepsy of infancy, epilepsy with persistent spike-and-wave during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy). The present invention is for use in the manufacture of a medicament for treating epilepsy, epilepsy syndromes, epilepsy symptoms, treatment-resistant or refractory epilepsy, or epileptic seizures, including epilepsy due to, or associated with, stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders (e.g. hyponatremia), or for use in the treatment of epileptic symptoms as part of a neurodegenerative disorder such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc.
[0032] In the context of the present invention, "optionally substituted" means that the indicated moiety may or may not be substituted, and if substituted, may be mono- or di-substituted. When there is no substituent indicated as an "optionally substituted" moiety, it will be understood that the position is held by a hydrogen atom.
[0033] A given range may be indicated interchangeably using "~" (a dash) or "to", e.g., the term "C 1~3 "Alkyl" is synonymous with C1 to C3 alkyl.
[0034] The terms "C1-C3 alkyl" and "C1-C6 alkyl" refer to an unbranched or branched saturated hydrocarbon having 1 up to 6, inclusive, carbon atoms. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, and t-butyl.
[0035] The term "C1-C3 alkoxy" refers to a moiety of formula -OR, where R refers to a C1-C3 alkyl as defined above.
[0036] The terms "C3-C6 cycloalkyl", "C3-C5 cycloalkyl", or "C3-C8 cycloalkyl" refer to saturated monocyclic rings. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
[0037] Route of Administration: The pharmaceutical compositions containing the compounds of the invention as defined above may be particularly formulated to be administered by any suitable route, such as oral, rectal, nasal, buccal, sublingual, transdermal, and parenteral (e.g. subcutaneous, intramuscular, and intravenous) routes, with the oral route being preferred.
[0038] It will be appreciated that the route will vary depending on the general condition and age of the subject being treated, the nature of the illness being treated, and the active ingredient.
[0039] Pharmaceutical Formulations and Excipients: Hereinafter, the term "excipient" or "pharmaceutical acceptable excipient" refers to pharmaceutical excipients including, but not limited to, fillers, antiadherents, binders, coatings, dyes, disintegrants, flavors, glidants, lubricants, preservatives, adsorbents, sweeteners, solvents, vehicles, and auxiliary agents.
[0040] The present invention also provides pharmaceutical compositions comprising the compounds of the present invention, such as one of the compounds disclosed in the experimental section of this specification.The present invention also provides a process for producing pharmaceutical compositions comprising the compounds of the present invention.The pharmaceutical compositions of the present invention can be formulated using pharma- ceutical acceptable excipients according to the prior art, such as those disclosed in Remington's "The Science and Practice of Pharmacy" 22nd edition (2012) (ed. Allen, Loyd V., Jr.).
[0041] Pharmaceutical compositions for oral administration include solid oral dosage forms such as tablets, capsules, powders, and granules, and liquid oral dosage forms such as solutions, emulsions, suspensions, and syrups, as well as powders or granules that are dissolved or suspended in a suitable liquid.
[0042] The solid oral dosage forms may be provided as discrete units (e.g., tablets or hard or soft capsules), each containing a predetermined amount of active ingredient and preferably one or more suitable excipients. If appropriate, the solid dosage forms may be prepared with coatings, such as enteric coatings, or may be formulated to provide modified release of the active ingredient, such as delayed or sustained release, according to methods well known in the art. If appropriate, the solid dosage forms may be in the form of disintegration in saliva, such as, for example, orodispersible tablets.
[0043] Examples of excipients suitable for solid oral formulations include, but are not limited to, microcrystalline cellulose, corn starch, lactose, mannitol, povidone, croscarmellose sodium, sucrose, cyclodextrin, talcum, gelatin, pectin, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Similarly, solid formulations may contain excipients for delayed or sustained release formulations known in the art, such as glyceryl monostearate or hypromellose. When solid materials are used for oral administration, the formulations may be prepared, for example, by mixing the active ingredient with a solid excipient and then compressing the mixture in a conventional tablet press, or, for example, the formulations may be placed in a hard capsule, for example in the form of a powder, pellet, or mini-tablet. The amount of solid excipients may vary widely, but typically ranges from about 25 mg to about 1 g per dosage unit.
[0044] Liquid oral dosage forms can be provided as, for example, elixirs, syrups, oral drops, or liquid-filled capsules. Liquid oral dosage forms can also be provided as powders for solution or suspension in aqueous or non-aqueous liquids. Examples of excipients suitable for liquid oral formulations include, but are not limited to, ethanol, propylene glycol, glycerol, polyethylene glycol, poloxamer, sorbitol, polysorbates, mono- and diglycerides, cyclodextrin, coconut oil, palm oil, and water. Liquid oral dosage forms can be prepared, for example, by dissolving or suspending the active ingredient in an aqueous or non-aqueous liquid, or by incorporating the active ingredient into an oil-in-water or water-in-oil liquid emulsion.
[0045] Additional excipients such as colorants, flavoring agents, and preservatives may be used in both solid and liquid oral formulations.
[0046] Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous solutions, dispersions, injection or infusion suspensions or emulsions, injection or infusion concentrates, and sterile powders to be reconstituted in sterile solutions or dispersions for injection or infusion before use. Examples of excipients suitable for parenteral formulations include, but are not limited to, water, coconut oil, palm oil, and cyclodextrin solutions. Aqueous formulations should be appropriately buffered if necessary and rendered isotonic with sufficient saline or glucose.
[0047] Other types of pharmaceutical compositions include suppositories, inhalants, creams, gels, skin patches, implants, and formulations for buccal or sublingual administration.
[0048] It is essential that excipients used in any pharmaceutical formulation be compatible with the active ingredient and according to the intended route of administration.
[0049] dose: In one embodiment, the compound of the present invention is administered in an amount of about 0.001 mg / kg body weight to about 100 mg / kg body weight per day. Specifically, the daily dosage may be within the range of 0.01 mg / kg body weight to about 50 mg / kg body weight per day. The exact dosage depends on the frequency and method of administration, sex, age, body weight, general condition of the subject to be treated, the nature and severity of the disease to be treated, any complications to be treated, the desired therapeutic effect, and other factors known to those skilled in the art.
[0050] A typical oral dosage for an adult is within the range of 0.1-1000 mg / day of a compound of the invention, for example 1-500 mg / day, such as 1-100 mg / day or 1-50 mg / day. Conveniently, the compound of the invention is administered in an amount of about 0.1-500 mg, for example 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg of a compound of the invention in a unit dosage form containing said compound.
[0051] Isomers and tautomeric forms: Where the compounds of the invention contain one or more chiral centers, a reference to any of the compounds encompasses enantiomerically or diastereomerically pure compounds as well as mixtures of enantiomers or diastereomers in any ratio, unless otherwise specified.
[0052] MDL Enhanced Stereo representation is used to represent the unknown stereochemistry of the compounds of the invention. Thus, the label "or1" on a chiral carbon atom is used to indicate that the absolute configuration at this atom is unknown, e.g., the configuration at this carbon atom is either (S) or (R).
[0053] Additionally, the chiral bond from the carbon atom labeled "or1" with an up or down wedge is an equivalent representation, e.g., the two figures have the same meaning, which is that the absolute configuration at the carbon atom labeled "or1" is unknown and can be either (S) or (R).
[0054] Thus, the use of the wedge up and wedge down bonds from the atom labeled "or1" is merely intended to provide a visual cue that the figures represent different stereoisomers and that the conformation at the carbon atom labeled "or1" is unknown.
[0055] Furthermore, some of the compounds of the present invention can exist in different tautomeric forms, and any tautomeric form that a compound is able to form is intended to be included within the scope of the invention.
[0056] Therapeutically effective amount: The term "therapeutically effective amount" of a compound in the context of the present invention means an amount sufficient to reduce, prevent, partially prevent, eliminate or delay the clinical manifestations of a given disease and its complications in a therapeutic intervention involving the administration of said compound. An amount sufficient to achieve this is defined as a "therapeutically effective amount". The effective amount for each purpose depends on the severity of the disease or injury, as well as the weight and general condition of the subject. It will be understood that the determination of the appropriate dosage can be achieved by constructing a matrix of values and testing various points in the matrix using routine experimentation, all of which is within the ordinary skill of a skilled physician.
[0057] Treatment and healing: In the context of the present invention, "treatment" or "treating" is intended to refer to the management and care of the patient with the aim of alleviating, arresting, partially arresting, eliminating or slowing the progression of clinical signs of the disease. The patient to be treated is preferably a mammal, in particular a human being.
[0058] All references cited in this specification, including publications, patent applications, and patents, are hereby incorporated by reference in their entirety and to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety (to the fullest extent permitted by law).
[0059] Treatment of epilepsy The classification of epilepsy may be based on ICD-10 (published by WHO in 2016) and is described in sections G40 and G41 and is included in the treatment of epilepsy according to the present invention. G40.0 Localization-related (focal) (partial) idiopathic epilepsies and epilepsy syndromes with localized onset of epileptic seizures G40.1 Localization-related (focal) (partial) symptomatic epilepsy and epilepsy syndromes with simple partial seizures G40.2 Localization-related (focal) (partial) symptomatic epilepsy and epilepsy syndromes with complex partial seizures G40.3 Idiopathic generalized epilepsy and epilepsy syndromes G40.4 Other generalized epilepsies and epilepsy syndromes G40.5 Specific epilepsy syndromes G40.6 Grand mal epilepsy, unspecified (with or without petit mal seizures) G40.7 Petit mal, unspecified, grand mal seizures without epilepsy G40.8 Other epilepsy G40.9 Epilepsy, unspecified G41 Status epilepticus
[0060] Treatment of epileptic seizures An epileptic seizure is a sudden, uncontrolled electrical disturbance in the brain. Seizures can cause changes in behavior, movement or emotion, and changes in level of consciousness. If a person has had more than one epileptic seizure, or is prone to having recurrent seizures, this is diagnosed as epilepsy.
[0061] There are many types of epileptic seizures, ranging in severity. The type of epileptic seizure depends on where and how it begins in the brain. Most epileptic seizures last between 30 seconds and 2 minutes. A seizure that lasts longer than 5 minutes is a medical emergency.
[0062] Focal seizures Focal seizures result from abnormal electrical activity in one area of the brain. Focal seizures can occur with or without loss of consciousness. Focal seizures with impaired cognition. These epileptic seizures are accompanied by an alteration or loss of consciousness or awareness. The person may stare into space and not respond normally to the environment, or make repetitive movements such as rubbing their hands together, chewing, swallowing, or walking in circles. Focal seizures without loss of consciousness. These seizures may change emotions or the way a person sees, smells, feels, tastes or hears, but the person does not lose consciousness. These seizures may also result in involuntary twitching of body parts such as the arms or legs, and spontaneous sensory symptoms such as tingling, dizziness and flashing lights.
[0063] Generalized seizures Epileptic seizures that seem to involve all areas of the brain are called generalized seizures. Different types of generalized seizures include: Absence seizures. Formerly known as petit mal seizures, absence seizures often occur in children and are characterized by staring into space or small body movements such as eye blinking or lip smacking. These epileptic seizures may occur in clusters and can cause brief loss of awareness. Tonic seizures. Tonic seizures cause muscles to stiffen. These epileptic seizures usually affect the muscles of the back, arms and legs. Atonic seizures. Also known as astatic seizures, atonic seizures cause a loss of muscle control, which can cause a person to suddenly collapse or fall. Clonic seizures. Clonic seizures are associated with repetitive or rhythmic jerking muscle movements. These epileptic seizures usually affect the neck, face and arms. Myoclonic seizures. Myoclonic seizures usually manifest as sudden, brief jerks or twitching of the arms and legs. Tonic-clonic seizures. Formerly known as grand mal epilepsy, tonic-clonic seizures are the most dramatic type of epileptic seizure and can cause sudden loss of consciousness, stiffening and shaking of the body, and sometimes loss of bladder control or tongue biting.
[0064] In many cases, attacks may be associated with or caused by: High fever, which may be related to an infection such as meningitis lack of sleep Low blood sodium (hyponatremia) that can occur with diuretic therapy Medications that lower the seizure threshold, such as certain painkillers, antidepressants or smoking cessation therapy Head trauma that causes areas of bleeding in the brain stroke Brain tumors Drugs such as amphetamines or cocaine alcohol
[0065] Headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
[0066] The use of any example or exemplary language herein (including "for instance," "for example," "eg," "such as," and "as such") is intended merely to facilitate easier understanding of the invention and does not limit the scope of the invention, unless otherwise specified.
[0067] The citation and incorporation of patent documents herein is done merely for convenience and does not reflect any opinion regarding the validity, patentability, and / or enforceability of such patent documents.
[0068] This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. The present invention may include the following aspects. [1] 2. A compound of formula I for use in the treatment of epilepsy, an epilepsy syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure. [ka] (In the formula, R1 is C 1 ~C 6 Alkyl, CF 3 , C.H. 2 CF 3 , C.F. 2 CHF 2、C 3 ~C 8 cycloalkyl, wherein said C 3 ~C 8 Cycloalkyl is one or two F, CHF 2 or CF 3 and R2 is H, C 1 ~C 6 Alkyl or CF 3 or Or, R1 and R2 are linked together to represent one or two F, CHF 2 or CF 3 C optionally substituted with 3 ~C 5 Forming a cycloalkyl, R3 is C 1 ~C 3 Alkyl or CH 2 O.C. 1~3 alkyl, 1 ~C 3 Alkyl or CH 2 O.C. 1~3 The alkyl may be optionally substituted with one or two F. R4 is OCF 3 , O.C.H. 2 CF 3 or OCHF 2 (selected from the group consisting of or a pharma- ceutically acceptable salt thereof. [2] R4 is OCF 3 or OCHF 2 2. The compound of claim 1, wherein: [3] R2 is H or CH 3 10. A compound according to any preceding claim, which is: or a pharma- ceutically acceptable salt thereof. [4] R3 is CH 2 O.C. 1~3 2. A compound according to any one of the preceding claims, or a pharma- ceutically acceptable salt thereof, which is alkyl. [5] R1 optionally represents one or two F, CHF 2 , or CF 3 C replaced by 3 ~C 4 2. A compound according to any one of the preceding claims, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl. [6] R1 is t-butyl, R2 is H, and R4 is OCF 3 , O.C.H. 2 CF 3 , O.C.H.F. 2 , or CF 3 10. A compound according to any one of the preceding claims, which is: or a pharma- ceutically acceptable salt thereof. [7] R1 and R2 join to form a cyclobutyl optionally substituted with 1 or 2 F, and R4 is OCF 3 , O.C.H. 2 CF 3 , O.C.H.F. 2 , or CF 3 10. A compound according to any one of the preceding claims, which is: or a pharma- ceutically acceptable salt thereof. [8] The compound is (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (R)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (S)-3-Hydroxy-4,4-dimthyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (S)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)propanamide, (R)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(R)-hydroxy-4,4-dimethylpentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(S)-hydroxy-4,4-dimethylpentanamide, (S)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (R)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (S)-2-(1-hydroxycyclobutyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)acetamide, (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, 4,4,4-trifluoro-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(trifluoromethyl)butanamide, (R)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide, (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)butanamide, (R)-2-(1-hydroxycyclopentyl)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (R)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (S)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (R)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, and 2. The compound of claim 1 selected from the group consisting of: (S)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, or a pharma- ceutically acceptable salt of any of these compounds. [9] 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharma- ceutical acceptable salt thereof and a pharma- ceutical acceptable excipient for use in the treatment of epilepsy, epilepsy syndromes, epilepsy symptoms, treatment-resistant or refractory epilepsy, or epileptic seizures.
[10] 10. The compound according to any one of claims 1 to 8 or a pharmaceutical salt thereof, or the pharmaceutical composition according to claim 9, for use in the treatment of focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g. severe myoclonic epilepsy of infancy, epilepsy with persistent spike-and-wave during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy, Ohtahara syndrome, or epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders (e.g. hyponatremia).
[11] 10. The compound according to any one of claims 1 to 8 or a pharmaceutical salt thereof, or the pharmaceutical composition according to claim 9, for use in the treatment of epileptic symptoms as part of a neurodegenerative disorder such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, or frontotemporal lobar degeneration.
[12] 10. A method of treating a patient suffering from or in need of treatment with epilepsy, an epileptic syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof.
[13] Focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g. severe myoclonic epilepsy of infancy, epilepsy with continuous spike-and-wave during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy). 10. A method of treating a patient in need thereof suffering from epilepsy due to rheumatoid arthritis (Ohtahara syndrome), or epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infection, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders (e.g. hyponatremia), or for use in treating epileptic symptoms as part of a neurodegenerative disorder, such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmacologic acceptable salt thereof.
[14] 10. Use of a compound according to claims 1 to 8 for the treatment of epilepsy, epilepsy syndromes, epileptic symptoms, treatment-resistant or refractory epilepsy, or epileptic seizures.
[15] 9. Use of a compound according to claims 1 to 8 or a pharma- tically acceptable salt thereof for use in the treatment of focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g. severe myoclonic epilepsy of infancy, epilepsy with persistent spikes and waves during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy, Ohtahara syndrome, or epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infections, or metabolic disorders (e.g. hyponatremia) or for use in the treatment of epileptic symptoms as part of a neurodegenerative disorder such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc.
[16] 9. The compound of claim 1 or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for treating epilepsy, an epileptic syndrome, an epileptic symptom, treatment-resistant or refractory epilepsy, or an epileptic seizure.
[17] 9. The compound according to claim 1 or a pharma- ceutical or pharma- ceutical salt thereof, for the manufacture of a medicament for focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, as well as other epilepsy syndromes (e.g. severe myoclonic epilepsy of infancy, epilepsy with persistent spike-and-wave during slow-wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome and early myoclonic encephalopathy-Ohtahara syndrome) or for use in the treatment of epileptic symptoms as part of a neurodegenerative disorder, such as Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, frontotemporal lobar degeneration, etc.
[0069] Experimental section Biological Evaluation: Cell culture Synthetic cDNA fragments encoding human Kv7.3 and human Kv7.2 separated by a P2A sequence were inserted into the pcDNA5 / FRT / TO vector using the BamHI and XhoI restriction sites. The constructs were then transfected into HEK Flp-In 293 cells using Lipofectamine2000. The transfected cells were grown in DMEM containing 10% (v / v) FBS and 1% PenStrep for 48 hours and subsequently maintained under selection in DMEM containing 10% (v / v) FBS, 1% PenStrep, and 200 μg / mL Hygromycin B at 37° C. in a humidified atmosphere of 5% CO2. The resulting stable hKv7.2 / hKv7.3 cell line (HEK-hKv7.2 / hKv7.3) was functionally tested by automated whole-cell patch clamp and showed typical Kv7 currents that were sensitive to XE991 and enhanced by retigabine.
[0070] Thallium influx assay Thallium influx assays of potassium channel activation were performed using the FLIPR Potassium Assay kit (Molecular Devices) as previously described (CD Weaver, et al., J Biomol Screen 2004, 9, 671-677). HEK-hKv7.2 / hKv7.3 cells were plated onto 96-well black-walled, clear-bottom culture dishes (Corning, Acton, MA, USA) at a density of 80,000 cells / well (100 μl / well) if cells were assayed the following day, or 40,000 cells / well (100 μl / well) if cells were assayed 2 days after plating.
[0071] On the day of the assay, the medium was removed, followed by the addition of 50 μL / well of test compound diluted to 2x final concentration in HBSS containing 20 mM HEPES and 50 μL / well of 2x dye loading buffer. The cells were then incubated for 60 min at room temperature in the dark. Tl + and K +Chloride-free stimulation buffer containing 1× (5× concentration: 5 mM in both cases) and test compounds at 1× final concentration were prepared during incubation. Cells were then assayed in a FDSS7000EX Functional Drug Screening System (Hamamatsu). Following baseline fluorescence signal readings at 0.1 Hz for 60 s and 1 Hz for 10 s, 25 μL / well of stimulation buffer was added and fluorescence was measured consecutively at 1 Hz for 50 s, followed by 0.1 Hz for 4 min. Compound effects were quantified using AUC as the reading and normalized to a reference compound included on each plate.
[0072] Compound Effects In the assays described above, the compounds of the present invention had the following biological activities:
[0073] [Table 1]
[0074] Synthesis of the Compounds of the Invention: General law: 400.13MHz on Bruker Avance III 400 devices, or 300.13MHz on Bruker Avance 300 devices, 1 H NMR spectra were recorded. Deuterated dimethylsulfoxide or deuterated chloroform were used as solvents. Tetramethylsilane was used as an internal reference standard. Chemical shift values are expressed as ppm relative to tetramethylsilane. The following abbreviations are used for the multiplicity of the NMR signals: s=singlet, d=doublet, t=triplet, q=quartet, qui=quintet, h=septet, dd=double doublet, ddd=double doublet, dt=double triplet, dq=double quartet, tt=triplet triplet, m=multiplet, and brs=broad singlet.
[0075] The chromatographic systems and methods for assessing chemical purity (LCMS method) and chiral purity (SFC and HPLC methods) are described below.
[0076]
Table 2
[0077]
Table 3
[0078]
Table 4
[0079]
Table 5
[0080]
Table 6
[0081]
Table 7
[0082]
Table 8
[0083]
Table 9
[0084]
Table 10
[0085]
Table 11
[0086]
Table 12
[0087]
Table 13
[0088]
Table 14
[0089]
Table 15
[0090]
Table 16
[0091]
Table 17
[0092]
Table 18
[0093]
Table 19
[0094]
Table 20
[0095]
Table 21
[0096]
Table 22
[0097] [Table 23]
[0098] [Table 24]
[0099] [Table 25]
[0100] General procedures for the synthesis of intermediates and compounds of general formula I are illustrated in Reaction Scheme 1 and specifically exemplified in the Preparative Section and Examples. Variations of the illustrated procedures known to those skilled in the art are within the scope of the invention.
[0101] The compounds of the present invention are prepared as illustrated in Scheme 1. Some of the compounds of general formula I contain two chiral carbon atoms and are formed as a mixture of diastereomers, in which case the diastereomers can be separated to give the single stereoisomers Ia and Ib. [ka] Scheme I shows the preparation of compounds of general formula I by two general routes. The first route is the synthesis of compounds of formula I by reaction of enantiomerically pure amines of general formula II with acids of general formula III via methods well known in the art for converting acids and amines to amides. This method involves forming reactive derivatives of the acids of formula III, including but not limited to activated esters and reactive mixed anhydrides, followed by condensation with amines of general formula II. One such method is to carry out the condensation in the presence of HATU ((1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) and a suitable base such as DIPEA (diisopropylethylamine) in a solvent such as dichloromethane.
[0102] Or, R 2 When R is H, compounds of general formula I can be prepared via a second general route, in which an intermediate of general formula V is treated with a suitable reducing agent, such as NaBH4, in a suitable solvent, such as methanol. Intermediates of formula V can be obtained from enantiomerically pure amines of general formula II and carboxylic acids of general formula IV (R = H). This transformation can be accomplished using similar reaction conditions as described above for the condensation of II and III to form I.
[0103] A variation of this procedure is the direct coupling reaction of chiral amines of general formula II with carboxylic esters of general formula IV (R = Me, Et). This reaction can be carried out by heating the reactants to reflux in a suitable solvent such as toluene in the presence of a suitable base such as DIPEA and in the presence of a suitable catalyst such as catalytic amount of DMAP (4-dimethylaminopyridine).
[0104] Optically active amines of general formula II can be prepared as outlined in Scheme 2. [ka] Aldehydes of general formula VI can be condensed with (R)-2-methylpropane-2-sulfinamide in the presence of a drying agent such as titanium(IV) isopropoxide or copper sulfate in a suitable solvent such as dichloroethane. The sulfinyl imine formed can be condensed with R 3 Treatment with MgBr gives the corresponding substituted (R)-2-methyl-N-((S)-1-aryl-alkyl)propane-2-sulfinamides (VII), which are converted to compounds of general formula II by treatment with an appropriate acid in a suitable solvent, such as HCl in MeOH.
[0105] The aldehydes of formula VI used to prepare the compounds of the present invention are either commercially available or can be prepared as described in the literature (see, for example, Journal of Medicinal Chemistry, 45(18), 3891-3904; 2002).
[0106] In one variation of this procedure, chiral amines of formula II can be obtained from aryl ketones via hydride reduction of intermediate sulfinyl imines using reagents such as L-Selectride, as shown in Scheme 3. [ka] The ketones used to prepare the compounds of the invention are either commercially available or can be prepared by methods known to those skilled in the art.
[0107] R 3 Another variation of this procedure, which is particularly suitable for obtaining chiral amines of general formula II, where R is a hydroxymethylene derivative, is outlined in Scheme 4. [ka] In this procedure, as described in JP 2017-095366, the glyoxylic acid sulfinyl imine formed during the condensation reaction of glyoxylic acid ester with (R)-2-methylpropane-2-sulfinamide can be reacted with a suitably substituted boronic acid using a suitable catalyst such as bis(acetonitrile)(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate in a suitable solvent such as dioxane. The resulting intermediate VIII can be hydrolyzed and re-protected to give intermediates of general formula IX, which can be further derivatized to give the desired R 3 In the compounds of the present invention, the carboxylate group of IX can be reduced to a hydroxymethylene using LAH (lithium aluminum hydride) under conditions such as CuI catalysis in a suitable solvent such as acetonitrile, and difluoromethylated using a suitable reagent such as 2,2-difluoro-2-(fluorosulfonyl)acetic acid.
[0108] Those skilled in the art will recognize that other transformations are possible from intermediates of general formula IX, and the present invention is intended to encompass such alternative transformations.
[0109] Carboxylic acids of general formula III can be prepared as outlined in Scheme 5. [ka] Ketones of general formula X are reacted with alkyl esters of bromoacetic acid, activated, for example, with Zn and iodine, to produce the corresponding aldol adducts. In an alternative procedure, the bromoacetic acid ester can be activated with Zn and TMSCl (trimethylsilyl chloride). In the final step, hydrolysis of the alkyl ester is achieved by treatment with a suitable base, such as NaOH or LiOH, in a suitable solvent, such as water, or an alcohol in water, followed by acidification with a suitable acid to give compounds of formula III.
[0110] Preparation of intermediates: IIa: (S)-1-(3-(trifluoromethoxy)phenyl)ethanamine hydrochloride [ka] Step 1: Preparation of (R)-2-methyl-N-(3-(trifluoromethoxy)benzylidene)propane-2-sulfinamide [ka] A mixture of 3-(trifluoromethoxy)benzaldehyde (24.8 g, 130.4 mmol), (R)-2-methylpropane-2-sulfinamide (19 g, 156.5 mmol), and CuSO4 (31.2 g, 195.7 mmol) in DCE (1,2-dichloroethane) (500 mL) was stirred at 55 °C for 24 h. The mixture was filtered and the filter cake was washed with DCM (dichloromethane) (200 mL). The organic phases were combined and concentrated. The residue was purified by flash silica gel chromatography (gradient) with an eluent of 0-15% ethyl acetate / petroleum ether to give the product (33 g, 86% yield). 1 H NMR (CDCl3400MHz): δ 8.59(s,1H),7.79-7.71(m,2H),7.53(t,J=8.0Hz,1H),7.38(d,J=8.0Hz,1H),1.28(s,9H).
[0111] Step 2: Preparation of (R)-2-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propane-2-sulfinamide [ka] To a solution of (R)-2-methyl-N-[[3-(trifluoromethoxy)phenyl]methylene]propane-2-sulfinamide (17.6 g, 59.8 mmol) in DCM (250 mL) was added MeMgBr (3 M in Et2O, 40 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, followed by 15 °C for 16 h. The mixture was cooled to 0 °C and saturated NH4Cl solution was added. The resulting mixture was extracted with DCM (100 mL × 2). The organic phase was washed with brine (200 mL), dried over Na2SO4, and concentrated. The residue was purified by flash silica gel chromatography (gradient) with an eluent of 0-50% ethyl acetate / petroleum ether to give the product (10.3 g, 56% yield). 1 H NMR(CDCl3400MHz):δ 7.37(t,J=8.0Hz,1H),7.27-7.24(m,1H),7.21(s,1H),7.13(br d,J=8.0Hz,1H),4.65-7.59(m,1H),3.32(br d,J=2.4Hz,1H),1.54(d,J=6.4Hz,3H),1.22(s,9H).
[0112] Step 3: Preparation of (S)-1-(3-(trifluoromethoxy)phenyl)ethanamine hydrochloride [ka] (R)-2-Methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propane-2-sulfinamide (10 g, 32.3 mmol) in MeOH (75 mL) was treated with HCl / MeOH (75 mL) and stirred for 16 h at 15° C. The mixture was concentrated to give (S)-1-(3-(trifluoromethoxy)phenyl)ethanamine hydrochloride (9 g, crude), which was used directly without further purification.
[0113] IIb: (1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethanamine hydrochloride [ka] Step 1: Preparation of 3-(2,2,2-trifluoroethoxy)benzaldehyde [ka] A mixture of 3-hydroxybenzaldehyde (5 g, 40.9 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (10.5 g, 45 mmol), and Cs2CO3 (26.7 g, 81.9 mmol) in DMF (60 mL) was stirred at 20° C. for 2 h. The mixture was filtered and the filter cake was washed with ethyl acetate (200 mL). The filtrate was washed with water (100 mL×2) and brine (100 mL×2), dried over Na2SO4, and concentrated. The crude was purified by column chromatography on silica gel (20% ethyl acetate in petroleum ether) to give the product (8.0 g, 95% yield). 1 HNMR (CDCl3400MHz): δ 7.58-7.51(m,2H),7.42(s,1H),7.27-7.25(m,1H),4.42(q,J=12.0Hz,J=8.0Hz,2H).
[0114] Step 2: Preparation of (R)-2-methyl-N-[[3-(2,2,2-trifluoro-ethoxy)phenyl]methylene]propane-2-sulfinamide [ka] A mixture of 3-(2,2,2-trifluoroethoxy)benzaldehyde (8.0 g, 39.2 mmol), (R)-2-methylpropane-2-sulfinamide (5.2 g, 43.1 mmol), and CuSO4 (9.4 g, 58.8 mmol) in DCE (70 mL) was stirred at 55° C. for 20 h. The mixture was filtered and the filter cake was washed with DCM (100 mL). The organic phase was concentrated and purified by column chromatography on silica gel (11% ethyl acetate in petroleum ether) to give the product (10.0 g, 83% yield). 1H NMR (CDCl3400MHz): δ 8.55(s,1H),7.50-7.42(m,3H),7.13(d,J=5.2Hz,1H),4.41(q,J=12.0Hz,J=8.0Hz,2H),1.27(s,9H).
[0115] Step 3: Preparation of (R)-2-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)propane-2-sulfinamide [ka] To a solution of (R)-2-methyl-N-[[3-(2,2,2-trifluoroethoxy)phenyl]methylene]propane-2-sulfinamide (10 g, 32.5 mmol) in DCM (100 mL) was added dropwise MeMgBr (3 M, 43 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, followed by 20 °C for 3 h. The mixture was cooled to 0 °C and saturated NH4Cl solution was added. The resulting mixture was extracted with DCM (100 mL x 2). The organic phase was washed with brine (200 mL), dried over Na2SO4 and concentrated. The crude was purified by column chromatography on silica gel (petroleum ether:ethyl acetate = 1:1) to give the product (9 g, 79% yield). 1 H NMR (CDCl3 400MHz): δ 7.27 (d, J=8.4Hz, 1H), 7.01 (d, J=8.4Hz, 1H), 6.93 (d, J=2.4Hz, 1H), 6.83 (dd, J=8.4Hz, J=2.4Hz, 1H), 4.56-4.54 (m, 1H), 4.34 (dd, J=16.4Hz, J=8.4Hz, 1H), 3.30 (br s, 1H), 1.51 (d, J=8.4Hz, 3H), 1.20 (s, 9H). No NH was observed.
[0116] Step 4: Preparation of (1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethanamine hydrochloride [ka] To a solution of (R)-2-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]propane-2-sulfinamide (9 g, 27.8 mmol) in MeOH (100 mL) was added HCl / MeOH (80 mL, 4 M) dropwise. The resulting mixture was stirred at 20° C. for 4 h and concentrated to give the crude product (8 g), which was used directly without further purification.
[0117] IIc: (S)-1-(3-(difluoromethoxy)phenyl)ethan-1-amine hydrochloride [ka] Step 1: Preparation of (R)-N-(3-(difluoromethoxy)benzylidene)-2-methylpropane-2-sulfinamide [ka] To a mixture of 3-(difluoromethoxy)benzaldehyde (2 g, 11.6 mmol) and 2-methylpropane-2-sulfinamide (1.7 g, 13.9 mmol) in DCE (60 mL) under N2 at 55 °C, CuSO4 (9.3 g, 58.1 mmol) was added. The mixture was stirred at 55 °C for 12 h, filtered, and the filtrate was concentrated. The crude product was purified by silica gel column eluted with petroleum ether / ethyl acetate = 20:1 to 10:1 to give (R)-N-(3-(difluoromethoxy)benzylidene)-2-methylpropane-2-sulfinamide (2.5 g, 70% yield).
[0118] Step 2: Preparation of (R)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide [ka] To a solution of (R)-N-(3-(difluoromethoxy)benzylidene)-2-methylpropane-2-sulfinamide (2 g, 7.3 mmol) in DCM (30 mL) was added bromo(methyl)magnesium (3 M in Et2O, 4.8 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, followed by 20 °C for 16 h. The reaction was quenched with NH4Cl (saturated aqueous solution, 10 mL) and the aqueous phase was extracted with ethyl acetate (30 mL × 3). The combined organic phase was washed with brine (40 mL × 2), dried over anhydrous Na2SO4, filtered, concentrated and purified by silica gel chromatography (petroleum ether / ethyl acetate = 5:1 to 1:1) to give (R)-N-((S)-1-(3-(difluoromethoxy)phenyl))-2-methylpropane-2-sulfinamide (960 mg, 45.4% yield).
[0119] Step 3: Preparation of (S)-1-(3-(difluoromethoxy)phenyl)ethanamine hydrochloride [ka] To a solution of (R)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide (0.8 g, 2.8 mmol) in MeOH (4 mL) was added HCl / MeOH (4 M, 2 mL). The resulting mixture was stirred at 25° C. for 3 h and the reaction was concentrated to give (S)-1-(3-(difluoromethoxy)phenyl)ethanamine in crude yield of 1.6 g, which was used directly without further purification.
[0120] IId: (S)-1-(3-(trifluoromethyl)phenyl)ethan-1-amine hydrochloride [ka] Step 1: Preparation of (R)-2-methyl-N-(3-(trifluoromethyl)benzylidene)propane-2-sulfinamide [ka] A mixture of 3-(trifluoromethyl)benzaldehyde (4.5 g, 25.8 mmol), (R)-2-methylpropane-2-sulfinamide (3.8 g, 31 mmol), and CuSO4 (6.2 g, 38.8 mmol) in DCE (20 mL) was stirred at 55° C. for 24 h. The mixture was filtered and the filter was washed with DCM (100 mL). The filtrate was concentrated and the residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate) to give the product in 4.6 g yield (58%). 1 H NMR (CDCl3,400MHz): δ 8.60(s,1H),8.09(s,1H),7.98(d,J=7.6Hz,1H),7.73(d,J=7.6Hz,1H),7.59(t,J=7.6Hz,1H),1.25(s,9H).
[0121] Step 2: Preparation of (R)-2-methyl-N-((S)-1-(3-trifluoro-methyl)phenyl)ethyl)propane-2-sulfinamide [ka] To a solution of (R)-2-methyl-N-(3-(trifluoromethyl)benzylidene)propane-2-sulfinamide (2 g, 7.2 mmol) in DCM (50 mL) was added MeMgBr (3 M in Et2O, 9.6 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, followed by 25 °C for 3 h. The reaction mixture was cooled to 0 °C and saturated NH4Cl solution was added. The mixture was extracted with DCM (50 mL × 3). The combined organic phase was washed with brine (50 mL × 2), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate) to give the desired product (1.3 g, 61% yield). 1 H NMR (CDCl3, 400 MHz): δ 7.40-7.65 (4H), 4.11-4.06 (m, 1H), 1.51 (d, J=6.8 Hz, 3H), 1.17 (s, 9H). No NH observed.
[0122] Step 3: Preparation of (S)-1-[3-(trifluoromethyl)phenyl]ethanamine hydrochloride [ka] To a solution of (R)-2-methyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)propane-2-sulfonamide (1.3 g, 4.4 mmol) in MeOH (20 mL) was added HCl / MeOH (4 M, 20 mL). The resulting mixture was stirred at 25° C. for 20 h and then concentrated to give the product in 850 mg yield. The crude was used directly without further purification.
[0123] IIe: (S)-1-(3-(trifluoromethoxy)phenyl)propan-1-amine hydrochloride [ka] Step 1: Preparation of (R)-2-methyl-N-(3-(trifluoromethoxy)benzylidene)propane-2-sulfinamide: [ka] A mixture of 3-(trifluoromethoxy)benzaldehyde (10.0 g, 52.60 mmol), (R)-2-methylpropane-2-sulfinamide (7.7 g, 63.1 mmol), and CuSO4 (12.6 g, 78.9 mmol) in DCE (200 mL) was stirred at 55 °C for 16 h. The mixture was filtered and the filter cake was washed with DCM (200 mL). The filtrate was concentrated. The residue was purified by flash chromatography on silica gel (eluent with 0-10% ethyl acetate / petroleum ether gradient) to give (R)-2-methyl-N-[[3-(trifluoromethoxy)phenyl]methylene]propane-2-sulfinamide in 12.6 g yield (81.7%).
[0124] Step 2: Preparation of (R)-2-methyl-N-((S)-1-(3-(trifluoro-methoxy)phenyl)propyl)propane-2-sulfinamide [ka] To a solution of (R)-2-methyl-N-(3-(trifluoromethoxy)benzylidene)propane-2-sulfinamide (2.0 g, 6.8 mmol) in DCM (40 mL) was added EtMgBr (3 M in Et2O, 9.1 mL) dropwise at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, followed by 20 °C for 3 h. The mixture was cooled to 0 °C and saturated aqueous NH4Cl (100 mL) was added. The mixture was extracted with DCM (100 mL × 2), the phases were separated, and the organic layer was washed with brine (200 mL), dried over Na2SO4, and concentrated. The residue was purified by flash silica gel chromatography (eluent with 0-50% ethyl acetate / petroleum ether gradient) to give the product (1.4 g, 62% yield).
[0125] Step 3: Preparation of (S)-1-[3-(trifluoromethoxy)phenyl]propan-1-amine hydrochloride [ka] To a solution of (R)-2-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)propane-2-sulfinamide (1.4 g, 4.2 mmol) in MeOH (40 mL) was added HCl / MeOH (4 M, 20 mL). The resulting mixture was stirred at 30° C. for 12 h and then concentrated to give crude (S)-1-[3-(trifluoromethoxy)phenyl]propan-1-amine hydrochloride, which was used without further purification (1 g).
[0126] IIf: (R)-2-Methoxy-1-(3-(trifluoromethoxy)phenyl)ethan-1-amine [ka] Step 1: Preparation of 2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethanone [ka] To a solution of 2-bromo-1-(3-(trifluoromethoxy)phenyl)ethanone (3.5 g, 12.4 mmol) in MeOH (60 mL) was added AgCO (3.8 g, 13.6 mmol) and BF 3. Et2O (2.1 g, 14.8 mmol) was added. The mixture was stirred at 50 °C under N2 for 16 h. The reaction mixture was filtered and concentrated. The residue was purified by column chromatography (SiO2, eluent of 0-5% ethyl acetate / petroleum ether) to give 2-methoxy-1-(3-(trifluoro-methoxy)phenyl)ethanone (2.1 g, 64% yield). 1 H NMR(400MHz,CDCl3)δ 7.87(d,J=8.0Hz,1H),7.80(s,1H),7.52(t,J=8.4Hz,1H),7.46-7.42(m,1H),4.68(s,2H),3.51(s,3H).
[0127] Step 2: Preparation of (R)-N-(2-methoxy-1-(3-(trifluoro-methoxy)phenyl)ethylidene)-2-methylpropane-2-sulfinamide [ka] To a solution of 2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethanone (500 mg, 2.1 mmol) in THF (15 mL) was added titanium(IV) isopropoxide (910 mg, 3.2 mmol) and (R)-2-methylpropane-2-sulfinamide (336 mg, 2.8 mmol). The mixture was stirred at 50 °C under N2 for 1 h. The reaction mixture was quenched with brine (40 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic phase was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, eluent of 0-10% ethyl acetate / petroleum ether) to give (R)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethylidene)-2-methylpropane-2-sulfinamide (160 mg, 20% yield).
[0128] Step 3: Preparation of (R)-N-((R)-2-Methoxy-1-(3-(trifluoro-methoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide [ka] To a solution of (R)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethylidene)-2-methylpropane-2-sulfinamide (160 mg, 0.5 mmol) in THF (5 mL) was added L-selectride (1 M in THF, 1.42 mmol, 1.42 mL) at 0 °C. The mixture was stirred at 20 °C for 16 h. The reaction mixture was diluted with methanol (20 mL) followed by filtration and concentration. The residue was purified by column chromatography (SiO2, eluent of 0-10% ethyl acetate / petroleum ether) to give the desired product (100 mg, 59% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 7.46-7.40(m,3H),7.27-7.25(m,1H),5.86(d,J=8.8Hz,1H),5.25(d,J=5.6Hz,2H),4.84-4.72(m,1H),3.25(s,3H),1.09(s,9H).
[0129] Step 4: Preparation of (R)-2-Methoxy-1-(3-(trifluoromethoxy)phenyl)ethanamine [ka] (R)-N-((R)-2-Methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide (280 mg, 0.8 mmol) in HCl / MeOH (10 mL, 4 M) was stirred at 20° C. for 14 h. The reaction mixture was concentrated, and the residue was diluted with water (30 mL), ammonium hydroxide was added to pH=8-9, and extracted with ethyl acetate (30 mL×2). The combined organic extracts were dried over MgSO4, filtered, and concentrated to give the product as a yellow oil (170 mg, 88% yield). The product was used directly without further purification.
[0130] IIg: (1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethanamine [ka] Step 1: Preparation of ethyl 2-[(R)-tert-butylsulfinyl]iminoacetate [ka] To a solution of ethyl 2-oxoacetate (7.5 g, 36.7 mmol) and (R)-2-methylpropane-2-sulfinamide (4.9 g, 40.4 mmol) in DCM (150 mL) was added CuSO4 (12.9 g, 80.8 mmol) and the reaction mixture was stirred at 25° C. for 24 h. The solid was filtered off and washed with ethyl acetate (50 mL) and the organic phases were combined and concentrated. The resulting residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate, 5 / 1) to give the desired product (5.1 g, 67.6% yield).
[0131] Step 2: Preparation of ethyl (2R)-2-[[(R)-tert-butylsulfinyl]amino]-2-[3-(trifluoromethoxy)phenyl]acetate [ka] To a solution of ethyl 2-[(R)-tert-butylsulfinyl]iminoacetate (7 g, 34.1 mmol) and [3-(trifluoromethoxy)phenyl]boronic acid (8.4 g, 40.9 mmol) in dioxane (100 mL) was added [Rh(COD)(MeCN)2]BF4 (1.3 g, 3.4 mmol) and the mixture was stirred at 80° C. for 16 h. The product was purified by silica gel chromatography (petroleum ether:ethyl acetate=5:1) to give 9.8 g (78%).
[0132] Step 3: Preparation of ethyl (2R)-2-amino-2-[3-(trifluoro-methoxy)phenyl]acetate hydrochloride [ka] To a solution of ethyl (2R)-2-[[(R)-tert-butylsulfinyl]amino]-2-[3-(trifluoromethoxy)phenyl]acetate (9.8 g, 26.7 mmol) in MeOH (100 mL) was added HCl / MeOH (4 M, 100 mL) and the mixture was stirred at 25° C. for 2 h, then concentrated to give ethyl (2R)-2-amino-2-[3-(trifluoromethoxy)phenyl]acetate (7.8 g, crude).
[0133] Step 4: Preparation of ethyl (2R)-2-(tert-butoxycarbonylamino)-2-[3-(trifluoromethoxy)phenyl]acetate [ka] To a mixture of ethyl (2R)-2-amino-2-[3-(trifluoromethoxy)phenyl]acetate hydrochloride (6 g, 20 mmol) in THF (150 mL) was added Boc2O (8.7 g, 40 mmol). NaHCO3 (1.7 g, 20 mmol) was then added to the solution and stirred at 25° C. for 16 h. The mixture was concentrated and purified by chromatography on silica (petroleum ether:ethyl acetate=10:1) to give the product (7.2 g, 99% yield).
[0134] Step 5: Preparation of tert-butyl N-[(1R)-2-hydroxy-1-[3-(trifluoromethoxy)phenyl]ethyl]carbamate [ka] To a suspension of LiAlH4 (1.7 g, 44 mmol) in THF (200 mL) was added ethyl (2R)-2-(tert-butoxycarbonylamino)-2-[3-(trifluoro-methoxy)phenyl]acetate (4 g, 11 mmol) in THF (25 mL) with ice cooling. After the addition, the reaction was warmed to 25°C and stirred for 2 h. Anhydrous magnesium sulfate was added, followed by successive addition of a drop of water and ethyl acetate. The insoluble material was filtered off through a Celite pad. The filtrate was concentrated and purified by chromatography on silica (SiO2; petroleum ether:ethyl acetate = 5:1) (2.1 g, 59% yield).
[0135] Step 6: Preparation of tert-butyl N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]carbamate [ka] To a solution of tert-butyl N-[(1R)-2-hydroxy-1-[3-(trifluoro-methoxy)phenyl]ethyl]carbamate (1.5 g, 4.7 mmol) in MeCN (20 mL) was added CuI (360 mg, 1.9 mmol) and stirred for 30 min under N2 atmosphere at 25° C. Subsequently, a solution of 2,2-difluoro-2-fluorosulfonyl-acetic acid (1.7 g, 9.3 mmol) in MeCN (5 mL) was added at 45° C. for 30 min and the reaction was stirred at 45° C. for 1 h. The mixture was concentrated, then diluted with ethyl acetate (100 mL), filtered and concentrated to give the desired product (1.5 g, crude).
[0136] Step 7: Preparation of (1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethanamine [ka] To a solution of tert-butyl N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]carbamate (1.5 g, 4 mmol) in MeOH (15 mL) at 25° C. was added HCl / MeOH (4 M in MeOH, 30 mL) and the reaction was stirred for 30 min at 25° C. Ammonium hydroxide (30%) was added to pH=9, and the solution was concentrated and purified by chromatography on silica (SiO2; petroleum ether:ethyl acetate=2:1) to give (1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethanamine (700 mg, 64% yield).
[0137] IIIa: 2-(1-hydroxycyclobutyl)acetic acid [ka] Step 1: Preparation of ethyl 2-(1-hydroxycyclobutyl)acetate [ka] To Zn (14.9 g, 228.3 mmol) in THF (20 mL) was added TMSCl (1.9 g, 17.1 mmol) in portions. The resulting mixture was stirred at 20 °C for 15 min and then brought to reflux. The reaction mixture was cooled to room temperature and ethyl 2-bromoacetate (28.6 g, 171.2 mmol) was added dropwise at such a rate that the reaction was gently boiling. The resulting mixture was stirred at 70 °C for 1 h, then at 20 °C for 1 h, followed by the addition of a solution of cyclobutanone (10 g, 142.7 mmol) in THF (5 mL). The mixture was stirred at 20 °C for an additional 2 h. The mixture was cooled to room temperature with NH 3. Poured into H2O (150 mL, 25%) and extracted with ethyl acetate (100 mL x 2). The organic layer was washed with water (200 mL x 2) and brine (100 mL x 2), dried over Na2SO4 and concentrated to give the product (12 g, crude). 1 H NMR(CDCl3400MHz):δ 4.20-4.14(m,2H),3.69(s,1H),2.65(s,2H),2.17-2.12(m,2H),2.03-2.00(m,2H),1.78(m,1H),1.58(m,1H),1.27(t,J=7.6Hz,3H).
[0138] Step 2: Preparation of 2-(1-hydroxycyclobutyl)acetic acid [ka] NaOH (6.3 g, 158.05 mmol) was dissolved in MeOH (150 mL) and H2O (50 mL) and ethyl 2-(1-hydroxycyclobutyl)acetate (10 g, 63.2 mmol) was added. The mixture was stirred at 20 °C for 16 h, then concentrated, and the residue was acidified with 2N HCl solution to pH = 2-3 and extracted with ethyl acetate (200 mL x 2). The organic extract was washed with water (100 mL x 2) and brine (100 mL x 2), dried over Na2SO4, and concentrated to give the crude product (6 g, crude). 1H NMR (CDCl3400MHz): δ 2.74(s,2H),2.23-2.05(m,4H),1.81(m,1H),1.63-1.58(m,1H).
[0139] IIIb: 2-(3,3-difluoro-1-hydroxycyclobutyl)acetic acid [ka] Step 1: Preparation of ethyl 2-(3,3-difluoro-1-hydroxy-cyclobutyl)acetate [ka] Ethyl 2-bromoacetate (378 mg, 2.3 mmol) was added dropwise to a solution of 3,3-difluorocyclobutanone (0.2 g, 1.9 mmol), Zn (198 mg, 3 mmol), and I2 (10 mg, 0.04 mmol) in THF (13 mL) under N2. The mixture was stirred at 55 °C for 6 h. H2SO4 (10%, 10 mL) was carefully added to the reaction mixture at 0 °C, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic extract was washed with NaHCO3 (sat. aq., 10 mL), dried over Na2SO4, and concentrated. The crude product (0.26 g) was used directly without further purification.
[0140] Step 2: Preparation of 2-(3,3-difluoro-1-hydroxy-cyclobutyl)acetic acid [ka] To a solution of ethyl 2-(3,3-difluoro-1-hydroxy-cyclobutyl)acetate (0.26 g, 1.3 mmol) in MeOH (10 mL) and H2O (2 mL) was added NaOH (107 mg, 2.7 mmol) at 0 °C. The mixture was stirred at 20 °C for 8 h. The reaction solution was cooled to 0 °C, and 1N HCl was added to the solution until the pH reached 1-2. The residue was diluted with brine (10 mL) and extracted with methyl-tert-butyl ether (30 mL x 5). The combined organic extracts were dried over Na2SO4, filtered, and concentrated. The crude product (0.24 g) was used without further purification.
[0141] IIIc: 3-hydroxy-4-methyl-3-(trifluoromethyl)pentanoic acid [ka] Step 1: Preparation of ethyl 3-hydroxy-4-methyl-3-(trifluoro-methyl)pentanoate [ka] To a mixture of Zn (560 mg, 8.6 mmol), I2 (7 mg, 0.03 mmol) in THF (5 mL) was added ethyl 2-bromoacetate (524 mg, 3.1 mmol) and 1,1,1-trifluoro-3-methyl-butan-2-one (0.4 g, 2.9 mmol) at 15 °C. The mixture was stirred at 60 °C for 6 h. H2SO4 (10% aqueous solution, 4 mL) was added and the mixture was extracted with ethyl acetate (10 mL x 4). The combined organic phase was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to give ethyl 3-hydroxy-4-methyl-3-(trifluoromethyl)pentanoate (1 g, crude).
[0142] Step 2: Preparation of 3-hydroxy-4-methyl-3-(trifluoromethyl)pentanoic acid [ka] A mixture of ethyl 3-hydroxy-4-methyl-3-(trifluoromethyl)pentanoate (1.5 g, crude) and LiOH.HO (552 mg, 13.2 mmol) in THF (20 mL) and HO (10 mL) was stirred at 15 °C for 16 h. The pH was adjusted to about 3 with 2 M HCl and the mixture was extracted with ethyl acetate (5 mL x 4). The combined organic extracts were washed with brine (15 mL), dried over NaSO, filtered and concentrated to give 3-hydroxy-4-methyl-3-(trifluoromethyl)pentanoic acid (1.1 g, crude) as a yellow solid, which was used directly in the next step without further purification.
[0143] IIId: 4,4,5,5-tetrafluoro-3-hydroxy-3-methylpentanoic acid [ka] Step 1: Preparation of ethyl 4,4,5,5-tetrafluoro-3-hydroxy-3-methylpentanoate [ka] Ethyl 2-bromoacetate (2.4 g, 14.3 mmol) was added dropwise to a solution of 3,3,4,4-tetrafluorobutan-2-one (2.00 g, 13.88 mmol), Zn (1.0 g, 15.7 mmol), and I (35.2 mg, 0.14 mmol) in THF (20 mL) under N at 20 °C. The mixture was stirred at 60 °C for 6 h. The reaction mixture was cooled to 0 °C and H2SO4 (15 ml, 10% aqueous solution) was carefully added. The mixture was extracted with ethyl acetate (80 mL × 3) and the combined organic extracts were washed with saturated aqueous NaHCO3 (30 mL), dried over Na2SO4, and concentrated. The title compound (2.5 g, crude) was obtained and used in the next step without further purification.
[0144] Step 2: Preparation of 4,4,5,5-tetrafluoro-3-hydroxy-3-methylpentanoic acid [ka] To a solution of ethyl 4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-pentanoate (2.5 g, 10.8 mmol) in MeOH (80 mL) and H2O (25 mL) was added NaOH (1.1 g, 26.9 mmol) at 0 °C. The mixture was stirred at 20 °C for 8 h and concentrated. The aqueous layer was acidified with 1N HCl aqueous solution to pH = 1-2 and extracted with methyl-tert-butyl ether (30 mL x 5). The combined organic extracts were dried over Na2SO4 and concentrated. The title compound was obtained (2.10 g, crude) and used without further purification.
[0145] IIIe: 5,5,5-trifluoro-3-hydroxy-3-methylpentanoic acid [ka] Step 1: Preparation of ethyl 5,5,5-trifluoro-3-hydroxy-3-methylpentanoate [ka] To a mixture of Zn (6.9 g, 104.7 mmol) and I2 (89 mg, 0.35 mmol) in THF (80 mL) was added 4,4,4-trifluorobutan-2-one (4.4 g, 34.9 mmol) and ethyl 2-bromoacetate (6.4 g, 38.4 mmol) at 15 °C. The mixture was stirred at 60 °C for 6 h. The reaction mixture was cooled to 0 °C and quenched with H2SO4 (100 mL, 10% aqueous solution). The mixture was extracted with ethyl acetate (15 mL x 3). The combined organic extracts were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated. The product was obtained (11.00 g, crude) and used directly without further purification.
[0146] Step 2: Preparation of 5,5,5-trifluoro-3-hydroxy-3-methylpentanoic acid [ka] A mixture of ethyl 5,5,5-trifluoro-3-hydroxy-3-methyl-pentanoate (11 g, crude) and NaOH (4.1 g, 102.7 mmol) in H2O (150 mL) was stirred at 15° C. for 16 h. The pH was adjusted to about 2 with saturated KHSO4 at 0° C., and the mixture was extracted with ethyl acetate (200 mL×3). The combined organic extracts were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated to give the product (10 g, crude).
[0147] IIIf: 3-(1-fluorocyclopropyl)-3-hydroxybutanoic acid [ka] Step 1: Preparation of ethyl 3-(1-fluorocyclopropyl)-3-hydroxybutanoate [ka] To a mixture of 1-(1-fluorocyclopropyl)ethanone (0.8 g, 7.8 mmol), Zn (1.5 g, 23.5 mmol), and I2 (20 mg, 0.8 mmol) in THF (15 mL) was added dropwise ethyl 2-bromoacetate (1.4 g, 8.6 mmol) at 15 °C. The mixture was stirred at 65 °C for 6 h. The reaction mixture was cooled to 0 °C and H2SO4 (10% aqueous solution, 10 mL) was added dropwise. The mixture was added water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic extracts were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated. The obtained product was used without further purification. Yield: 1.6 g, crude.
[0148] Step 2: Preparation of 3-(1-fluorocyclopropyl)-3-hydroxybutanoic acid [ka] A mixture of ethyl 3-(1-fluorocyclopropyl)-3-hydroxy-butanoate (1.6 g, crude) and NaOH (670 mg, 16.8 mmol) in H2O (30 mL) was stirred at 15 °C for 16 h. The pH was adjusted to about 2 with 10% HCl (aq). The mixture was extracted with ethyl acetate (20 mL x 4) and the combined organic extracts were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated to give the crude product, which was used directly without further purification. (1.50 g, crude).
[0149] IIIg: 3-Cyclopropyl-3-hydroxybutanoic acid [ka] Step 1: Preparation of methyl 3-cyclopropyl-3-hydroxybutanoate [ka] To Zn (12.4 g, 190.2 mmol) in THF (150 mL) was added TMSCl (1.3 g, 11.9 mmol), and the resulting mixture was stirred at 20 °C for 15 min, then heated to 70 °C. Heating was discontinued, and methyl 2-bromoacetate (21.8 g, 142.7 mmol) was added dropwise at such a rate that the ether was gently boiling. The resulting mixture was stirred at 70 °C for 1 h, then at 20 °C for 1 h, followed by the addition of a solution of 1-cyclopropylethanone (10 g, 118.9 mmol) in THF (50 mL). The reaction was stirred at 20 °C for 16 h. The mixture was poured into NH3·H2O (100 mL, 28%) on ice and extracted with ethyl acetate (150 mL × 2). The organic extract was washed with water (150 mL) and brine (150 mL), dried over Na2SO4 and concentrated to give the desired product (8.9 g, crude).
[0150] Step 2: Preparation of 3-cyclopropyl-3-hydroxybutanoic acid [ka] A mixture of crude methyl 3-cyclopropyl-3-hydroxybutanoate (8.9 g, 56.3 mmol) and LiOH·HO (11.8 g, 281.3 mmol) in THF (100 mL) and HO (50 mL) was stirred at 20 °C for 16 h. HO (50 mL) was added and extracted with ethyl acetate (100 mL × 2). The organic extract was discarded. The pH of the aqueous layer was adjusted to about 5 with 2 N HCl and extracted with ethyl acetate (100 mL × 3), and the combined organic fractions were washed with brine (100 mL × 10), dried over Na2SO4, filtered, and concentrated to give the desired product (5.1 g) in 30% overall yield. 1 H NMR(400MHz,CDCl3)δ 2.67-2.51(m,2H),1.25(s,3H),0.90-1.00(m,1H),0.33-0.50(m,4H).
[0151] IVa: Ethyl 3-[1-(difluoromethyl)cyclopropyl]-3-oxo-propanoate [ka] Step 1: Preparation of ethyl 3-[1-(difluoromethyl)cyclopropyl]-3-oxo-propanoate [ka] Et3N (2.34 g, 23.5 mmol) and MgCl2 (1.8 g, 18.4 mmol) were added to a suspension of (3-ethoxy-3-oxo-propanoyl)oxy potassium salt (2.6 g, 15.4 mmol) in MeCN (30 mL) and stirred at 20 °C for 2 h. A pre-stirred mixture of CDI (carbonyl-diimidazole) (1.4 g, 8.8 mmol) and 1-(difluoromethyl)cyclopropanecarboxylic acid (1 g, 7.4 mmol) in MeCN (20 mL) was added at 0 °C and stirred at 20 °C for 14 h. The reaction mixture was diluted with H2O (30 mL) and extracted with ethyl acetate (80 mL × 2). The combined organic extracts were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on silica gel (eluent: 0-10% ethyl acetate / petroleum ether gradient) to give the product in a yield of 0.98 g (65%).
[0152] IVb: Ethyl 3-oxo-3-[1-(trifluoromethyl)cyclopropyl]propanoate [ka] Step 1: Preparation of ethyl 3-oxo-3-[1-(trifluoromethyl)cyclopropyl]propanoate [ka] Et3N (6.3 g, 62.3 mmol) and MgCl2 (4.6 g, 48.7 mmol) were added to a suspension of potassium 3-ethoxy-3-oxo-propanoate (6.9 g, 40.5 mmol) in CH3CN (25 mL) and stirred at 20 °C for 2 h. A pre-stirred mixture of carbonyldiimidazole (CDI) (3.8 g, 23.3 mmol) and 1-(trifluoromethyl)cyclopropanecarboxylic acid (3 g, 19.5 mmol) in CH3CN (25 mL) was added at 0 °C and stirred at 20 °C for 14 h. The mixture was poured into water (20 mL). The aqueous phase was extracted with ethyl acetate (30 mL × 3). The combined organic phase was washed with brine (40 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (petroleum ether / ethyl acetate=30:1 to 10:1) to give the product in 3.5 g yield (80%).
[0153] Va: 4,4-dimethyl-3-oxo-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide [ka] A solution of (1S)-1-[3-(trifluoromethoxy)phenyl]ethanamine hydrochloride (IIa) (5 g, 20.69 mmol), 4,4-dimethyl-3-oxo-pentanoic acid (3.28 g, 22.76 mmol), HATU (9.44 g, 24.83 mmol), and DIPEA (8 g, 62.1 mmol) in DCM (250 mL) was stirred at 25° C. for 16 h. The resulting mixture was washed with water (500 mL) and extracted with DCM (500 mL×2). The organic layer was washed with brine (350 mL×2), dried over Na2SO4, and concentrated. The residue was purified by chromatography (SiO2; petroleum ether / ethyl acetate = 1:0 to 3:1) to give 4,4-dimethyl-3-oxo-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide (11.2 g, crude).
[0154] The following intermediates were prepared by a similar method to Va using the relevant intermediates.
[0155] Vb: 4,4-Dimethyl-3-oxo-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide [ka] Prepared from IIb (2.6 g, 10.1 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (1.6 g, 11.1 mmol). Yield: 2.6g (75%).
[0156] Vc: (S)-N-(1-(3-(difluoromethoxy)phenyl)ethyl)-4,4-dimethyl-3-oxopentanamide [ka] Prepared from IIc (0.8 g, 4.3 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (616 mg, 4.3 mmol). Yield: 1.3g crude
[0157] Vd: (S)-4,4-dimethyl-3-oxo-N-(1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide [ka] Prepared from IId (850 mg, 3.77 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (597 mg, 4.14 mmol). Yield: 1.12g (94%).
[0158] Ve: (S)-4,4-dimethyl-3-oxo-N-(1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide [ka] Prepared from IIe (1.04 g, 4.07 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (645 mg, 4.47 mmol). Yield: 1.28g (91%).
[0159] Vf: (S)-4-methyl-3-oxo-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] Prepared from IIb (2.89 g, 11.32 mmol) and 4-methyl-3-oxo-pentanoic acid (1.62 g). Yield: 2.6g (69%).
[0160] Vi: (S)-4-Methyl-3-oxo-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Prepared from IIa (2.7 g, 13.16 mmol) and 4-methyl-3-oxo-pentanoic acid (1.60 g). Yield: 2.00g (47%).
[0161] Vj: N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethyl-3-oxo-pentanamide [ka] Prepared from IIg (600 mg, 2.21 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (382 mg, 2.66 mmol). Yield: 520 mg (51%).
[0162] Vk: N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethyl-3-oxo-pentanamide [ka] Prepared from IIf (40 mg, 0.15 mmol) and 4,4-dimethyl-3-oxo-pentanoic acid (25 mg, 0.17 mmol). Yield: 100mg (94%).
[0163] Vg: 3-[1-(difluoromethyl)cyclopropyl]-3-oxo-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propanamide [ka] A mixture of IIa (557 mg, 2.30 mmol), IVa (0.95 g, 4.61 mmol), DMAP (57 mg, 0.46 mmol), and EtN (2.33 g, 23.04 mmol) in toluene (30 mL) was degassed and purged with N three times, and the mixture was subsequently stirred under N at 110 °C for 12 h. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (eluent with 0–35% ethyl acetate / petroleum ether gradient) to give the desired product (0.61 g, 72% yield).
[0164] The following were prepared by a similar method to that described for Vg using the relevant intermediates:
[0165] Vh: 3-oxo-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-[1-(trifluoromethyl)cyclopropyl]propanamide [ka] Prepared from IVb (2 g, 8.9 mmol) and IIa (915.3 mg, 4.5 mmol). Yield: 1.7g (97%).
[0166] Vl: (S)-3-(3,3-difluorocyclobutyl)-3-oxo-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] Prepared from methyl 3-(3,3-difluorocyclobutyl)-3-oxopropanoate (600 mg, 3.12 mmol) and IIa (377 mg, 1.56 mmol). Yield: 470mg (82%). 1 H NMR(CDCl3,400MHz)δ 7.39-7.35(m,1H),7.26-7.23(m,1H),7.15-7.11(m,2H),5.16-5.08(m,1H),3.44(d,J=2.4Hz,2H),2.86-2.71(m,5H),1.51(d,J=7.2Hz,3H). EXAMPLES
[0167] Example 1a: (S)-3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] and Example 1b: (R)-3-Hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide [ka] Step 1: Preparation of 3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide [ka] To a mixture of 4,4-dimethyl-3-oxo-N-[(1S)-1-[3-((trifluoromethoxy)phenyl]ethyl]pentanamide (Va) (5.6 g, 16.90 mmol) in MeOH (50 mL) was added NaBH4 (1.28 g, 33.8 mmol) in portions at 0 °C. The mixture was stirred at 0 °C for 1 h. Water (50 mL) was added in small portions at 0 °C. This reaction was repeated twice on the same scale and the crude products from three separate reactions were combined and processed as follows:
[0168] The mixture was concentrated to remove MeOH, followed by extraction with ethyl acetate (100 mL×4). The combined organic extracts were washed with brine (50 mL×3), dried over Na2SO4, filtered, and concentrated to give 3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide (16.5 g, crude).
[0169] Step 2: Separation of (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide and (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide [ka] 3-Hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide (27 g, 83 mmol) was isolated by chromatography.
[0170] Example 1a: Yield: 10.5g 1H NMR (CDCl3400MHz): δ7.33(t,J=8.0Hz,1H),7.22(d,J=8.0Hz,1H),7.05-7.20(2H),6.40(br,1H),5.15(m ,1H),3.64(dd,J=2.0Hz,8.4Hz,1H),3.05(br,1H),2.15-2.40(m,2H),1.45(d,J=7.2Hz,3H),0.88(s,9H). LC-MS: R =2.548 min (LCMS method 1), m / z=334.0[M+H] + . SFC:t R =1.89 minutes (SFC method 4), de=95%, [α] D 20 =-71.7(c=0.72g / 100mL, MeOH).
[0171] Example 1b: Yield: 10.5g 1 H NMR (CDCl3400MHz): δ7.32(t,J=8.0Hz,1H),7.22(d,J=7.6Hz,1H),7.13(s,1H),7.10-7.07(m,1H),6.52(d,J=7.6Hz,1H),5.13-5.06(m, 1H),3.62(dd,J=2.0Hz,8.4Hz,1H),3.45-3.33(m,1H),2.38-2.33(m,1H),2.23-2.17(m,1H),1.44(d,J=7.2Hz,3H),0.88(s,9H).LC-MS:t R =2.553 minutes (LCMS method 1), m / z=334.0[M+H] + . SFC:t R =1.87 minutes (SFC method 5), de=100%, [α] D 20 =-42.3(c=0.61g / 100mL, MeOH).
[0172] The following examples were prepared by methods similar to those described for 1a and 1b using the relevant intermediates.
[0173] Example 2a: 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] and Example 2b: 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide was prepared from Vb in 84% yield.
[0174] Step 2: Separation of (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide and (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] 3-Hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide (0.84 g, 2.52 mmol) was separated by chiral SFC.
[0175] Example 2a: Yield: 0.25g 1H NMR(CDCl3,400MHz)δ 7.30(t,J=7.6Hz,1H),7.01(d,J=7.6Hz,1H),6.93(s,1H),6.85(dd,J=8.4Hz,2.8Hz,1H),6.08(br d,J=5.2Hz,1H),5.13(m,1H),4.36(q,J=16.0Hz,8.0Hz,2H),3.68(dd,J=10.4Hz,3.0 Hz,1H),3.24(d,J=3.2Hz,1H),2.39-2.23(m,2H),1.49(d,J=6.8Hz,3H),0.93(s,9H) LC-MS:t R =2.68 minutes (LCMS method 2), m / z=348.0[M+H] + . SFC:t R =1.78 points (SFC method 1), de=98.3%, [α] D 20 = -68.0 (c = 0.25, MeOH).
[0176] Example 2b: Yield: 0.37g 1 H NMR(CDCl3,400MHz)δ 7.29(t,J=8.0Hz,1H),7.01(d,J=8.0Hz,1H),6.94(s,1H),6.84(dd,J=8.0,2.4Hz,1H),6.04(m,1H),5.13(m,1H),4.36(q,J= 16.0Hz,8.0Hz,2H),3.70-3.67(m,1H),3.15(d,J=2.8Hz,1H),2.40-1.96(m,2H),1.50(d,J=7.2Hz,3H),0.93(s,9H)LC-MS:t R =2.543 minutes (LCMS method 2), m / z=348.0[M+H] + . SFC:t R =1.87 points (SFC method 1), de=92.0%, [α] D 20 =-53.3 (c=0.21, MeOH).
[0177] Example 3a: N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] and Example 3b: N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] Step 1: Preparation of N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] It was prepared from Vc (yield 84%).
[0178] Step 2: Separation of (S)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide and (R)-N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide (450 mg) was separated by chiral SFC.
[0179] Example 3a: Yield: 168mg 1H NMR(CDCl3400MHz):δ 7.31-7.29(m,1H),7.26-7.24(m,1H),7.16-7.14(m,1H),7.10-6.98(m,1H),6.49(t,J=76Hz,1H),6.14(brs,1H),5.14- 5.07(m,1H),3.66(d,J=10.4Hz,1H),3.17(s,1H),2.38-2.34(m,1H),2.28-2.18(m,1H),1.47-1.40(m,3H),0.98(s,9H). LC-MS:t R =2.161 points (LCMS method 3), m / z=316.1[M+H] + . SFC:t R =2.15 points (SFC method 2), de=96.6%, [α] D 20 =-16(c=0.25, MeOH).
[0180] Example 3b: Yield: 126mg 1 H NMR(CDCl3400MHz):δ 7.34-7.30(m,1H),7.16-7.12(m,1H),7.04-6.97(m,2H),6.31(t,J=76Hz,1H),6.14(brs,1H),5.12-5.06(m ,1H),3.67-3.62(m,1H),3.29(s,1H),2.37-2.31(m,1H),2.26-2.19(m,1H),1.47-1.43(m,3H),0.98(s,9H). LC-MS:t R =2.16 points (LCMS method 3), m / z=316.1[M+H] + . SFC:t R =2.42 points (SFC method 2), de=100%, [α] D 20 =-57.6 (c=0.5, MeOH).
[0181] Example 4a: 3-ヒドロキシ-4, 4-ジメチル-N-((S)-1 -(3-(トリフルオロ-メチル)フェニル)エチル)ペンタンアミド [ka] and Example 4b: 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoro-methyl)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide [ka] Prepared from Vd (980 mg, 87% yield).
[0182] Step 2: Separation of (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide and (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide [ka] 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide was separated by chromatography on silica (petroleum ether:ethyl acetate=3:1).
[0183] Example 4a: Yield: 220 mg 1 H NMR(CDCl3400MHz):δ 7.56(s,1H),7.52-7.43(m,3H),6.22-6.21(m,1H),5.21-5.14(m,1H),3.68-3.64(m,1H),3.1 4(d,J=3.2Hz,1H),2.40-2.36(m,1H),2.26-2.20(m,1H),1.50(d,J=7.2Hz,3H),0.91(s,9H). LC-MS: R =2.48 min (LCMS method 1), m / z=318.0[M+H] + . SFC:t R =1.56 minutes (SFC method 3), de=100%, [α] D 20 =-25.5(c=0.19g / 100mL, MeOH).
[0184] Example 4b: Yield: 270 mg 1 H NMR(CDCl3400MHz):δ 7.54-7.45(m,4H),6.25-6.23(m,1H),5.20-5.13(m,1H),3.69-3.65(m,1H),3.24(d,J =3.2Hz,1H),2.39-2.35(m,1H),2.27-2.21(m,1H),1.49(d,J=6.8Hz,3H),0.91(s,9H). LC-MS: R =2.48 min (LCMS method 1), m / z=318.0[M+H] + . SFC:t R =1.93 minutes (SFC method 3), de=100%, [α] D 20 =-61.4(c=0.57g / 100mL, MeOH).
[0185] Example 8a: 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoro-methoxy)phenyl)propyl)pentanamide [ka] and Example 8b: 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoro-methoxy)phenyl)propyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide [ka] Prepared from Ve, yield: 1.22 g
[0186] Step 2: Separation of (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide and (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide [ka] 3-Hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide was separated by flash chromatography on silica gel (0-30% ethyl acetate / petroleum ether gradient eluent).
[0187] Example 8a: Yield: 0.51 g 1 H NMR(CDCl3400MHz):δ 7.40-7.34(m,1H),7.25-7.21(m,1H),7.14-7.10(m,2H),6.22-6.15(m,1H),4.92(q,J=7.6Hz,1H),3. 71-3.65(m,1H),3.21(d,J=2.8Hz,1H),2.40-2.23(m,2H),1.82(q,J=7.2Hz,2H),0.94-0.90(m,12H). LC-MS: R =2.486 min (LCMS method 5), m / z=348.0[M+H] + . SFC:t R =1.775 minutes (SFC method 3), de=98.7%, [α] D 20 =-80.0(c=0.31g / 100mL, MeOH).
[0188] Example 8b: Yield: 0.59 g 1 H NMR(CDCl3400MHz):δ 7.39-7.33(m,1H),7.25-7.20(m,1H),7.14-7.09(m,2H),6.24(br d,J=8.0Hz,1H),4.92(q,J=7.6Hz,1H),3.69-3.63(m,1H),3.15(d,J=3.2Hz,1H),2.40-2.25(m,2H),1.81(q,J=7.6Hz,2H),0.94-0.90(m,12H). LC-MS: R =2.506 min (LCMS method 5), m / z=348.0[M+H] + . SFC:t R =1.609 minutes (SFC method 3), de=98.7%, [α] D 20 =-40.0(c=0.27g / 100mL, MeOH).
[0189] Example 11a: 3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] and Example 11b: 3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propenamide [ka] Step 1: Preparation of 3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] Prepared from Vl. Yield: 300 mg (60.7%).
[0190] Step 2: Separation of (S)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide from (R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] Separation was carried out by chiral SFC.
[0191] Example 11a: Yield: 90 mg 1 H NMR(400MHz,CDCl3)δ 7.42-7.35(m,1H),7.25(d,J=7.6Hz,1H),7.17-7.11(m,2H),5.93(d,J=7.2Hz,1H),5.19-5.09(m,1H), 4.01-3.93(m,1H),3.86(d,J=3.6Hz,1H),2.62-2.48(m,3H),2.46-2.13(m,4H),1.50(d,J=6.8Hz,3H). LC-MS: R =2.513 min (LCMS method 2), m / z=368.0[M+H] + . SFC:t R =2.169 minutes (SFC method 3), de=97.4%, [α] D 20 =-42.0 (c=2.0 mg / mL, MeOH).
[0192] Example 11b: Yield: 90 mg 1H NMR(400MHz,CDCl3)δ 7.40-7.36(m,1H),7.25(d,J=7.6Hz,1H),7.16-7.11(m,2H),5.99(d,J=7.2Hz,1H),5.18-5.09(m,1H),3.98(t,J=7.2Hz,1H),3.83(br s,1H),2.61-2.49(m,3H),2.45-2.12(m,4H),1.50(d,J=6.8Hz,3H). LC-MS: R =2.235 minutes (LCMS method 3), m / z=368.0[M+H] + . SFC:t R =2.013 minutes (SFC method 3), de=99.6%, [α] D 20 =-17.0 (c=2.0 mg / mL, MeOH).
[0193] Example 12a: 3-Hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoro-ethoxy)phenyl)ethyl)pentanamide [ka] and Example 12b: 3-Hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoro-ethoxy)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] Prepared from Vf. Yield: 0.88g (87%)
[0194] Step 2: Separation of (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide and (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide [ka] 3-Hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide was separated by chiral SFC.
[0195] Example 12a: Yield: 0.362 g 1 H NMR(CDCl3,400MHz)δ 7.31(t,J=8.0Hz,1H),7.01(d,J=7.2Hz,1H),6.92(t,J=2.0Hz,1H),6.83(dd,J=8.0,2.4Hz,1H),6.08(br d,J=7.2Hz,1H),5.12(m,1H),4.36(q,J=8.0Hz,2H),3.80-3.74(m,1H),3.36(d,J=3.2Hz,1H) ),2.37-2.27(m,2H),1.73-1.70(m,1H),1.49(d,J=6.8Hz,3H),0.94(dd,J=10.4,6.8Hz,6H); LC-MS: R =2.531 min (LCMS method 2), m / z=334.0[M+H] + . SFC:t R =2.864 minutes (SFC method 3), de=99.2%, [α] D 20 =-74.0 (c=0.20, MeOH).
[0196] Example 12b: Yield: 0.245 g 1H NMR(CDCl3,400MHz)δ 7.30(t,J=8.0Hz,1H),7.00(d,J=8.0Hz,1H),6.92(t,J=2.0Hz,1H),6.83(dd,J=8.0,2.4Hz,1H),6.14(br d,J=6.8Hz,1H),5.11(m,1H),4.36(q,J=16.4,8.0Hz,2H),3.79-3.75(m,1H),3.34(d,J=3.2Hz, 1H),2.38-2.25(m,2H),1.73-1.62(m,1H),1.49(d,J=7.2Hz,3H),0.94(dd,J=10.0,6.8Hz,6H); LC-MS: R =2.543 min (LCMS method 2), m / z=334.0[M+H] + . SFC:t R =3.071 minutes (SFC method 3), de=99.7%, [α] D 20 =-47.0 (c=0.20, MeOH).
[0197] Example 14a: 3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] and Example 14b: 3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] Step 1: Preparation of 3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] Prepared from Vg. Yield: 0.58g
[0198] Step 2: Separation of (S)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide and (R)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide [ka] 3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide was separated by flash silica gel chromatography (0-41% ethyl acetate / petroleum ether gradient elution).
[0199] Example 14a: 0.2g 1 H NMR(CDCl3400MHz):δ 7.40-7.34(m,1H),7.26-7.22(m,1H),7.16-7.11(m,2H),6.11(br d,J=7.2Hz,1H),5.88(t,J=58.4Hz,1H),5.12(quintet,J=7.2Hz,1H),3.91(d,J=3.2Hz,1H),3.81 -3.75(m,1H),2.62-2.48(m,2H),1.49(d,J=7.2Hz,3H),0.87-0.76(m,2H),0.76-0.62(m,2H). LC-MS: R =2.448 min (LCMS method 1), m / z=368.0[M+H] + . SFC:t R =2.282 minutes (SFC method 3), de=97.9%, [α] D 20 =-62.0(c=0.27g / 100mL, MeOH).
[0200] Example 14b: Yield: 0.18 g 1 H NMR(CDCl3400MHz):δ 7.40-7.34(m,1H),7.24(d,J=7.6Hz,1H),7.17-7.10(m,2H),6.06(br d,J=7.6Hz,1H),5.84(t,J=58.4Hz,1H),5.12(quintet,J=7.2Hz,1H),3.86-3.79(m,2H),2.5 5(d,J=5.6Hz,2H),1.50(d,J=6.8Hz,3H),0.83-0.75(m,2H),0.74-0.66(m,2H).LC-MS:t R =2.467 min (LCMS method 1), m / z=368.0[M+H] + . SFC:t R =1.960 minutes (SFC method 3), de=96.3%, [α] D 20 =-54.4(c=0.25g / 100mL, MeOH).
[0201] Example 16a: 3-Hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide [ka] and Example 16b: 3-Hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide [ka] Step 1: Preparation of 3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide [ka] Vh and used directly in the next step.
[0202] Step 2: Separation of (R)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide from (S)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide [ka] The crude product from step 1 was separated by chiral SFC to give the desired product.
[0203] Example 16a: Yield: 556 mg 1 H NMR (DMSO-d 6 400MHz):δ 8.37(d,J=7.6Hz,1H),7.43-7.39(m,1H),7.31-7.29(m,1H),7.23(s,1H),7.18-7.16(m,1H),5.21(d,J=5.2 Hz,1H),4.96-4.88(m,1H),3.85-3.75(m,1H),2.35-2.25(m,2H),1.30(d,J=7.2Hz,3H),0.85-0.77(m,4H). LC-MS: R =2.626 min (LCMS method 2), m / z=386.0[M+H] + . SFC:t R =2.010 minutes (SFC method 3), de=99.9%, [α] D 20 =-56.0 (c=0.01g / 100mL, MeOH)
[0204] Example 16b: Yield: 692 mg 1 H NMR (DMSO-d 6400MHz):δ 8.36(d,J=8.0Hz,1H),7.42-7.38(m,1H),7.32(d,J=8.0Hz,1H),7.25(s,1H),7.17-7.15(m,1H),5.20(d,J=5 .2Hz,1H),4.95-4.91(m,1H),3.75-3.85(m,1H),2.25-2.35(m,2H),1.30(d,J=6.8Hz,3H),0.80-0.79(m,4H). LC-MS: R =2.649 min (LCMS method 2), m / z=386.0[M+H] + . SFC:t R =1.615 minutes (SFC method 3), de=95.7%, [α] D 20 =-46.0(c=0.01g / 100mL, MeOH).
[0205] Example 20a: 3-Hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] and Example 20b: 3-Hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Prepared from Vi. Yield: 1.80g (72%)
[0206] Step 2: Separation of (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide and (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] 3-Hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide was separated by chromatography (SiO2, petroleum ether / ethyl acetate = 0:1 to 1:1).
[0207] Example 20a: 250 mg 1 H NMR(CDCl3,400MHz)δ 7.37(t,J=8.0Hz,1H),7.27-7.21(m,1H),7.16-7.11(m,2H),6.15(d,J=6. 8Hz, 1H), 5.16 (quintet, J = 6.8Hz, 1H), 3.83-3.74 (m, 1H), 3.26 (d, J = 3.2Hz, 1H) ),2.37(dd,J=15.2,3.2Hz,1H),2.31(dd,J=15.2,8.8Hz,1H),1.74-1.68( m,1H),1.50(d,J=6.8Hz,3H),0.95(d,J=6.8Hz,3H),0.93(d,J=6.8Hz,3H). LC-MS: R =2.629 min (LCMS method 2), m / z=320.0[M+H] + . SFC:t R =2.404 minutes (SFC method 13), de=98.6%, [α] D 20 =-80.0(c=0.475g / 100mL, MeOH).
[0208] Example 20b: Yield: 470 mg 1H NMR (CDCl3, 400MHz) δ 7.37(t,J=7.6Hz,1H),7.28-7.23(m,1H),7.16(s,1H),7.14-7.11(m,1H),6.1 9(d,J=6.8Hz,1H),5.15(quintet,J=7.2Hz,1H),3.80-3.74(m,1H),3.20(d,J=3.6 Hz,1H),2.38(dd,J=14.8,2.4Hz,1H),2.30(dd,J=14.8,9.2Hz,1H),1.73-1.6 6(m,1H),1.49(d,J=6.8Hz,3H),0.95(d,J=6.8Hz,3H),0.93(d,J=6.8Hz,3H). LC-MS: R =2.654 min (LCMS method 2), m / z=320.0[M+H] + . SFC:t R =1.979 minutes (SFC method 13), de=100%, [α] D 20 =-52.0(c=0.53g / 100mL, MeOH).
[0209] Example 21a: N-((R)-2-(difluoromethoxy)-1-(3-(trifluoro-methoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] and Example 21b: N-((R)-2-(difluoromethoxy)-1-(3-(trifluoro-methoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] Step 1: Preparation of N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide [ka] Prepared from Vj. Yield = 350 mg, (96%)
[0210] Step 2: Separation of N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(R)-hydroxy-4,4-dimethyl-pentanamide from N-((R)-2-(difluoromethoxy)-1-(3-(trifluoro-methoxy)phenyl)ethyl)-3-(S)-hydroxy-4,4-dimethylpentanamide [ka] N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide was separated by chiral SFC.
[0211] Example 21a: Yield: 98 mg 1 H NMR(CDCl3400MHz):δ 7.39(t,J=8.0Hz,1H),7.29-7.26(m,1H),7.20(s,1H),7.16(d,J=8.0Hz,1H),6.65(d,J=7.6Hz,1H),6.22(t,J=74.0Hz,1H),5 .34-5.30(m,1H),4.18-4.09(m,2H),3.69(d,J=10.8Hz,1H),2.91(s,1H),2.45-2.43(m,1H),2.34-2.27(m,1H),0.93(s,9H). LC-MS: R =2.471 min (LCMS method 5), m / z=400.0[M+H] + . SFC:t R =1.935 minutes (SFC method 14), de=98.2%, [α] D 20 =-2.4 (c=1.0 g / 100 mL, MeCN).
[0212] Example 21b: 160 mg 1 H NMR (DMSO-d 6400MHz):δ 8.54(d,J=8.4Hz,1H),7.49(d,J=8.0Hz,1H),7.41(d,J=8.0Hz,1H),7.39(s,1H),7.28(d,J=8.0Hz,1H),6.67(t,J=76.0Hz,1H) ,5.21-5.18(m,1H),4.67(s,1H),4.04-3.98(m,2H),3.53(d,J=10.2Hz,1H),2.31-2.26(m,1H),2.19-2.12(m,1H),0.82(s,9H). LC-MS: R =2.496 min (LCMS method 5), m / z=400.0[M+H] + . SFC:t R =2.461 minutes (SFC method 14), de=97.1%, [α] D 20 =-11.2(c=1.0g / 100mL, MeCN).
[0213] Example 22a: 3-Hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoro-methoxy)phenyl]ethyl]-4,4-dimethyl-pentanamide [ka] and Example 22b: 3-Hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoro-methoxy)phenyl]ethyl]-4,4-dimethyl-pentanamide [ka] Step 1: Preparation of 3-hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethyl-pentanamide [ka] Prepared from Vk. Yield: 84 mg, (60%).
[0214] Step 2: Separation of (S)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide from (R)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide [ka] 3-Hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethyl-pentanamide was separated by chiral SFC.
[0215] Example 22a: Yield: 40 mg 1 H NMR(CDCl3400MHz):δ 7.35(t,J=8.0Hz,1H),7.27-7.26(m,1H),7.20(s,1H),7.12(d,J=7.6Hz,1H),6.66(d,J=7.2Hz,1H),5.1 8-5.14(m,1H),3.70-3.60(m,3H),3.36(s,3H),2.44(d,J=14.8Hz,1H),2.25-2.33(m,1H),0.93(s,9H). LC-MS: R =2.410 min (LCMS method 3), m / z=364.0[M+H] + . SFC:t R =1.889 minutes (SFC method 16), de=100%, [α] D 20 =-0.4 (c=1.0 g / 100 mL, MeCN).
[0216] Example 22b: Yield: 38 mg 1H NMR(CDCl3400MHz):δ 7.36(t,J=8.0Hz,1H),7.27-7.25(m,1H),7.18(s,1H),7.12(d,J=7.6Hz,1H),6.56(d,J=7.2Hz,1H),5.20-5.1 5(m,1H),3.69-3.60(m,3H),3.40(s,1H),3.36(s,3H),2.44(d,J=14.8Hz,1H),2.25-2.33(m,1H),0.93(s,9H). LC-MS: R =2.523 min (LCMS method 1), m / z=364.0[M+H] + . SFC:t R =2.106 minutes (SFC method 16), de=98.2%, [α] D 20 =-2.7 (c=1.0 g / 100 mL, MeCN).
[0217] Example 5: (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide [ka] Step 1: [ka] A mixture of (1S)-1-[3-(trifluoromethoxy)phenyl]ethanamine hydrochloride (IIa) (291 mg, 1.20 mmol), 2-(3,3-difluoro-1-hydroxy-cyclobutyl)acetic acid (IIIb) (0.22 g, 1.32 mmol), HATU (549 mg, 1.44 mmol), and DIPEA (467 mg, 3.6 mmol) in DCM (15 mL) was stirred at 20 °C for 16 h. The mixture was washed with water (40 mL × 2) and extracted with DCM (40 mL). The organic layer was washed with brine (10 mL × 2), dried over Na2SO4, and concentrated. The residue was purified by flash chromatography on silica gel (eluent of 0-35% ethyl acetate / petroleum ether gradient) to give the product (0.2 g, 47% yield). 1 H NMR(CDCl3,400MHz):δ 7.41-7.37(m,1H),7.26-7.23(m,1H),7.18-7.13(m,2H),5.93(br d,J=6.8Hz,1H),5.15(quintet,J=7.2Hz,1H),5.01(br s,1H),2.84-2.42(m,6H),1.53(d,J=6.8Hz,3H). LC-MS: R =2.53 min (LCMS method 2), m / z=354.0[M+H] + . HPLC: R = 13.3 min, (chiral HPLC method 1), de = 100%. [α] 20 D =-51.1(c=0.23g / 100mL, MeOH).
[0218] The following examples were prepared in a similar manner to Example 5 using the relevant staring materials.
[0219] Example 6: (S)-2-(1-hydroxycyclobutyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)acetamide [ka] Step 1: Preparation of (S)-2-(1-hydroxycyclobutyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)acetamide [ka] Prepared from IIb (5.0 g, 22.81 mmol) and IIIa (3.3 g, 25.09 mmol). Yield: 5.2g (45%). 1 H NMR(CDCl3,400MHz):δ 7.29(t,J=8.0Hz,1H),6.99(d,J=7.6Hz,1H),6.90(s,1H),6.83(dd,J=8.4Hz,J=2.4Hz,1H),6.25(d,J=6.8Hz,1H),5.14-5.07(m,1H),4.35(q, J=8.0Hz,2H),4.14(s,2H),2.53(s,2H),2.15-1.99(m,4H),1.76(m,1H),1.55(m,1H),1.48(d,J=6.8Hz,3H). LC-MS: R =2.49 min (LCMS method 2), m / z=332.0[M+H] + . SFC:t R =2.67 minutes (SFC method 3), de=96.9%, [α] D 20 =-69.0 (c=0.1, MeOH).
[0220] Example 7a: 3-Hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoro-ethoxy)phenyl)ethyl)-3-(trifluoromethyl)pentanamide [ka] and Example 7b: 3-Hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoro-ethoxy)phenyl)ethyl)-3-(trifluoromethyl)pentanamide [ka] Step 1: Preparation of 3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)-3-(trifluoromethyl)pentanamide [ka] Prepared from IIb and IIIc. Yield: 0.65 g (crude). The crude was used directly without purification.
[0221] Step 2: Separation of (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide from (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide [ka] Separation was achieved by flash silica gel chromatography (0-15% ethyl acetate / petroleum ether gradient elution).
[0222] Example 7a: Yield: 0.29 g 1 H NMR (CDCl3, 400MHz): δ 7.32(t,J=8.0Hz,1H),7.00(d,J=7.6Hz,1H),6.91(d,J=2.0Hz,1H),6.85(dd ,J=8.0,2.4Hz,1H),6.32(s,1H),5.99(d,J=7.6Hz,1H).5.15-5.07(m,1H),4. 36(q,J=8.0Hz,2H),2.45(d,J=15.2Hz,1H),2.34(d,J=15.2Hz,1H),2.13-2.0 6(m,1H),1.50(d,J=6.8Hz,3H),1.03(d,J=6.8Hz,3H),0.97(d,J=6.8Hz,3H). LC-MS: R=2.883 min (LCMS method 4), m / z=402.0[M+H] + . SFC:t R =2.454 minutes (SFC method 6), de=100%, [α] D 20 =-43.5(c=0.0058g / mL, MeOH).
[0223] Example 7b: Yield: 0.23 g 1 H NMR(CDCl3,400MHz):δ 7.32(t,J=8.0Hz,1H),7.00(d,J=7.6Hz,1H),6.91-6.84(m,2H),6.33(s,1H),5.90(d,J=7.6Hz,1H),5.19-5.10(m,1H),4.35(q,J=8.4Hz,2 H),2.51(d,J=14.8Hz,1H),2.35(d,J=14.8Hz,1H),2.15-2.06(m,1H),1.52(d,J=7.2Hz,3H),1.05(d,J=6.8Hz,3H),0.98(d,J=6.8Hz,3H). LC-MS: R =2.834 min (LCMS method 6), m / z=402.0[M+H] + . SFC:t R =2.262 minutes (SFC method 7), de=99.8%, [α] D 20 =-37.1(c=0.0034g / mL, MeOH).
[0224] Example 9: 4,4,4-trifluoro-3-hydroxy-N-[(1S)-1-[3-(trifluoro-methoxy)phenyl]ethyl]-3-(trifluoromethyl)butanamide [ka] Step 1: [ka] Prepared from IIa and 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butanoic acid. Yield: 650 mg (63%) 1 H NMR (DMSO-d 6 400MHz):δ 9.14(d,J=7.2Hz,1H),8.45(s,1H),7.44(t,J=8.0Hz,1H),7.32(d,J=7.6Hz,1H),7.24 (s,1H),7.21(d,J=8.4Hz,1H),5.01-4.93(m,1H),2.89(s,2H),1.34(d,J=6.8Hz,3H). LC-MS: R =2.850 min (LCMS method 4), m / z=413.9[M+H] + . Chiral HPLC: R =15.61 min, (HPLC method 2), de=98.4%, [α] D 20 =-41.1(c=0.185g / 100mL, MeOH).
[0225] Example 10a: 4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] and Example 10b: 4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Prepared from IIa and IIId. Yield: 1 g (53%)
[0226] Step 2: Separation of (R)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide and (S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] The diastereomers were separated by chiral SFC.
[0227] Example 10a: Yield = 0.268g 1 H NMR(CDCl3400MHz):δ 7.42-7.36(m,1H),7.24(d,J=7.6Hz,1H),7.17-7.12(m,2H),6.28-5.97(m,2H),5.93(br d,J=6.0Hz,1H),5.16(quintet,J=6.8Hz,1H),2.69(d,J=15.2Hz,1H),2.37(d,J=15.2Hz,1H),1.53(d,J=6.8Hz,3H),1.40(s,3H). LC-MS: R =2.759 min (LCMS method 2), m / z=392.0[M+H] + . SFC:t R =1.550 minutes (SFC method 15), de=100%, [α] D 20 =-50.5(c=0.19g / 100mL, MeOH).
[0228] Example 10b: Yield = 0.148 g 1H NMR(CDCl3400MHz):δ 7.44-7.36(m,1H),7.26(d,J=8.0Hz,1H),7.19-7.12(m,2H),6.33-6.01(m,2H),5.91(br d,J=6.8Hz,1H),5.16(quintet,J=6.8Hz,1H),2.70(d,J=15.2Hz,1H),2.35(d,J=15.2Hz,1H),1.52(d,J=6.8Hz,3H),1.35(s,3H). LC-MS: R =2.782 min (LCMS method 2), m / z=392.0[M+H] + . SFC:t R =1.329 minutes (SFC method 15), de=100%, [α] D 20 =-48.6(c=0.21g / 100mL, MeOH).
[0229] Example 13a: 5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxyphenyl)ethyl)pentanamide [ka] and Example 13b: 5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Step 1: Preparation of 5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Prepared from IIa and IIIe. Yield: 1 g (43%)
[0230] Step 2: Separation of (R)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide and (S)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide [ka] Separation was achieved by flash chromatography on silica gel (0-31% ethyl acetate / petroleum ether gradient elution).
[0231] Example 13a: Yield = 0.421 g 1 H NMR(CDCl3400MHz):δ 7.42-7.36(m,1H),7.24(d,J=8.0Hz,1H),7.17-7.12(m,2H),5.98(br d,J=6.8Hz,1H),5.15(quintet,J=6.8Hz,1H),5.00(s,1H),2.54-2.44(m,2H),2.44-2.31(m,2H),1.51(d,J=7.2Hz,3H),1.38(s,3H). LC-MS: R =2.666 min (LCMS method 2), m / z=374.0[M+H] + . SFC:t R =1.277 minutes (SFC method 8), de=100%, [α] D 20 =-51.3(c=0.23g / 100mL, MeOH).
[0232] Example 13b: 0.261 g 1 H NMR(CDCl3400MHz):δ 7.42-7.36(m,1H),7.25(d,J=8.0Hz,1H),7.17-7.12(m,2H),5.96(br d,J=7.2Hz,1H),5.16(quintet,J=6.8Hz,1H),4.98(s,1H),2.57-2.36(m,4H),1.52(d,J=6.8Hz,3H),1.36(s,3H). LC-MS: R =2.674 min (LCMS method 2), m / z=374.0[M+H] + . SFC:t R =1.197 min (SFC method 8), de=93.4%, [α] D 20 =-43.2(c=0.19g / 100mL, MeOH).
[0233] Example 15a: 3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide [ka] and Example 15b: 3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide [ka] Step 1: Preparation of 3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide [ka] Prepared from IIa and IIIf. The crude material was used directly in the next step.
[0234] Step 2: Separation of (R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide and (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)butanamide [ka] Separation was achieved by flash chromatography on silica gel (0-30% ethyl acetate / petroleum ether gradient elution).
[0235] Example 15a: Yield = 1.05g 1 H NMR(CDCl3400MHz):δ 7.37(t,J=8.0Hz,1H),7.27-7.24(m,1H),7.17-7.12(m,2H),6.11(br s,1H),5.18-5.10(m,1H),5.02(s,1H),2.61(dd,J=14.4,2.4Hz,1H),2.46(dd,J=14.4 ,1.6Hz,1H),1.51(d,J=7.2Hz,3H),1.33(s,3H),0.78-0.68(m,3H),0.52-0.50(m,1H). LC-MS: R =2.359 min (LCMS method 3), m / z=350.0[M+H] + . SFC:t R =2.027 minutes (SFC method 9), de=93.9%, [α] D 20 =-48.3(c=0.24g / 100mL, MeOH).
[0236] Example 15b: Yield: 0.80 g 1 H NMR(CDCl3400MHz):δ 7.38(t,J=8.0Hz,1H),7.27-7.23(m,1H),7.15-7.12(m,2H),6.06(d,J=7.2Hz,1H),5.19-5.11(m,1H),4.99(s,1H),2.62(dd,J=14.4 ,2.0Hz,1H),2.47(d,J=1.6Hz,1H),2.43(d,J=1.6Hz,1H),1.51(d,J=7.2Hz,3H),1.33(s,3H),0.97-0.87(m,1H),0.85-0.81(m,3H). LC-MS: R =2.655 min (LCMS method 2), m / z=350.0[M+H] + . SFC:t R=1.937 min (SFC method 9), de=98.7%, [α] D 20 =-64.4(c=0.27g / 100mL, MeOH).
[0237] Example 17: (R)-2-(1-hydroxycyclopentyl)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide [ka] Prepared from IIa and 2-(1-hydroxycyclopentyl)acetic acid. Yield: 30 mg (12.8%). 1 H NMR(400MHz,CDCl3)δ 7.37(t,J=8.0Hz,1H),7.26-7.25(m,1H),7.19(s,1H),7.16-7.11(m,1H),6.66(br d,J=7.2Hz,1H),5.21-5.15(m,1H),3.82(s,1H),3.70-3.60(m,2H),3.37(s,3H),2.59-2.49(m,2H),1.86-1.81(m,4H),1.59-1.56(m,4H). LC-MS: R =2.481 min (LCMS method 2), m / z=362.0[M+H] + . SFC:t R =2.33 minutes (SFC method 10), de=100%, [α] D 20 =-44.0, (c=1 mg / mL, MeOH).
[0238] Example 18a: 3-Cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] and Example 18b: 3-Cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] Step 1: Preparation of 3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] Prepared from IIb and IIIg. Yield: 3.7g (30.9%)
[0239] Step 2: Separation of (R)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide and (S)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] Separation was carried out by chiral SFC.
[0240] Example 18a: Yield: 1.59 g 1 H NMR(400MHz,DMSO-d6)δ 8.32(d,J=8.0Hz,1H),7.28(t,J=8.0Hz,1H),7.04-6.98(m,2H),6.93-6.90(m,1H),4.97-4.91(m,1H),4.73(q,J=8. 8Hz,2H),4.61(s,1H),2.37-2.25(m,2H),1.34(d,J=7.2Hz,3H),1.10(s,3H),0.87-0.84(m,1H),0.30-0.09(m,4H). LC-MS: R =2.629 min (LCMS method 2), m / z=328.0[M+H-18] + . SFC:t R =3.154 minutes (SFC method 11), de=99.7%, [α] D 20 =-62.0 (c=2 mg / mL, MeOH).
[0241] Example 18b: Yield: 1.44 g 1 H NMR(400MHz,DMSO-d6)δ 8.19(br d,J=8.0Hz,1H),7.12(t,J=8.0Hz,1H),6.87-6.79(m,2H),6.77-6.74(m,1H),4.81-4.73(m,1H),4.57(q,J=8.8H z,2H),4.42(s,1H),2.19-2.08(m,2H),1.17(d,J=6.8Hz,3H),0.94(s,3H),0.73-0.64(m,1H),0.19-0.00(m,4H). LC-MS: R =2.643 min (LCMS method 2), m / z=328.0[M+H-18] + . SFC:t R =2.570 minutes (SFC method 11), de=97.0%, [α] D 20 =-58.0 (c=2mg / mL, MeOH)
[0242] Example 19a: 4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] and Example 19b: 4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] Step 1: Preparation of 4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka] Prepared from IIb and 4,4,4-trifluoro-3-hydroxy-3-methyl-butanoic acid. Yield: 6.67 g (73%)
[0243] Step 2: Separation of (R)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy))ethyl)butanamide and (S)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide [ka]
[0244] Example 19a: 2.3g 1 H NMR(CDCl3,400MHz)δ 7.32(t,J=8.0Hz,1H),6.99(d,J=7.8Hz,1H),6.92-6.88(m,1H),6.88-6.83(m,1H),5.99(br d,J=6.8Hz,1H),5.84(s,1H),5.12(quintet,J=7.2Hz,1H),4.35(q,J=8.0Hz,2H) ,2.51(dd,J=53.2,15.2Hz,2H),1.51(d,J=7.2Hz,3H),1.41(s,3H);LC-MS:t R =2.732 minutes (LCMS method 2), m / z=374.0[M+H] + . SFC:t R =1.721 min (SFC method 12), de=99.6%, [α] D 20 =-51.0 (c=0.20, MeOH).
[0245] Example 19b: 0.86 g 1 H NMR(CDCl3,400MHz)δ 7.33(t,J=8.0Hz,1H),7.00(d,J=7.2Hz,1H),6.93-6.90(m,1H),6.88-6.83(m,1H),5.98-5.91(m,1H),5.91(s,1H) ,5.12(quintet,J=7.2Hz,1H),4.36(q,J=8.0Hz,2H),2.50(dd,J=57.6,14.8Hz,2H),1.51(d,J=6.8Hz,3H),1.39(s,3H); LC-MS: R =2.737 min (LCMS method 2), m / z=374.0[M+H] + . SFC:t R =1.904 minutes (SFC method 12), de=100%, [α] D 20 =-57.1 (c=0.21, MeOH).
[0246] Example: Epilepsy in Kv7 Genetic loss-of-function mutations in Kv7 channels have been described to lead to epileptic seizures and convulsions in KCNQ epileptic encephalopathies (KCNQEE) and benign familial neonatal convulsions (BFNC) (Schroeder BC et al. Nature. 1998 Dec 17;396(6712):687-90; Kato M, et al. Epilepsy. 2013 Jul;54(7):1282-7).
[0247] Retigabine is approved for the treatment of partial seizures and has also been reported to affect epileptic seizures in epilepsy syndromes such as Lennox-Gastaut syndrome and Dravet syndrome. Retigabine has been described to affect several pharmacological targets and to act as a Kv7 activator. A relationship between Kv7 activation thresholds and clinically effective exposure has been described (Gunthorpe MJ et al,Epilepsya.2012 Mar;53(3):412-24).
[0248] Kv7 activators are known to demonstrate anticonvulsant properties across a variety of rodent epileptic seizure models for partial and generalized seizures (Roeloffs R et al. J Pharmacol Exp Ther. 2008 Sep;326(3):818-28), including animal models for specific epilepsy syndromes such as Dravet syndrome (Reid CA et al. Brain. 2014 Jun;137(Pt6):1701-15. doi:10.1093 / brain / awu077. Epub 2014 Apr 17) and KCNQ epileptic encephalopathy (KCNQEE) (Ihara Y, et al. PLoS One. 2016 Feb 24;11(2).
[0249] (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide was tested for its anticonvulsant properties in both mice and rats using the Maximal Electroshock Seizure Threshold Test (MEST) (Giardin and Gasior, Curr Protocols in Pharm, 5.22.1-5.22.37, June 2009), in which corneal electrodes are used to induce tonic convulsions. In mice, a dose-dependent significant increase in the current required to induce an electroshock convulsion, i.e., the seizure threshold, occurred. In rats, the effects of both pretreatment with a single acute dose of (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide and pretreatment with repeated doses (once daily for 15 days) resulted in a significant increase in the seizure threshold.
[0250] Data generated from n=12-16 treatment groups were used to calculate CC50 sem values according to the method of Kimball et al Radiat Res. 1957;7(1):1-12.
[0251] Significant differences between drug-treated animals and controls were assessed according to Litchfield and Wilcoxon, Pharmacol Exp Ther. 1949;96(1):99-113.
Claims
1. Epilepsy, epilepsy syndromes, epilepsy symptoms, treatment-resistant or refractory epilepsy, or Compounds of formula I for the treatment of epileptic seizures 【Chemistry 1】 (In the formula, R1 is C 1 ~C 6 Alkyl, CF 3 , C.H. 2 CF 3 , C.F. 2 CHF 2 , C 3 ~C 8 cycloalkyl, wherein said C 3 ~C 8 Cycloalkyl is one or two F, CHF 2 Or CF 3 and R2 is H, C 1 ~C 6 Alkyl or CF 3 or Or, R1 and R2 are bonded to each other to form one or two F, CHF 2 Or CF 3 C optionally substituted with 3 ~C 5 Forming a cycloalkyl, R3 is C 1 ~C 3 Alkyl or CH 2 O-C 1~3 alkyl, 1 ~C 3 Alkyl or CH 2 O-C 1~3 The alkyl may be optionally substituted with one or two F. R4 is OCF 3 , O.C.H. 2 CF 3 or OCHF 2 (selected from the group consisting of or a pharma- ceutical composition comprising a compound of formula (I) or a pharma- ceutical acceptable salt thereof, The pharmaceutical composition further comprises a pharma- ceutically acceptable excipient.
2. R4 is OCF 3 or OCHF 2 The pharmaceutical composition of claim 1 ,
3. R2 is H or CH 3 The pharmaceutical composition according to claim 1 or 2,
4. R3 is CH 2 O-C 1~3 The pharmaceutical composition according to any one of claims 1 to 3, wherein the aryl group is alkyl.
5. R1 is optionally 1 or 2 F, CHF 2 , or C.F. 3 C substituted with 3 ~C 4 The pharmaceutical composition according to any one of claims 1 to 4, wherein the aryl group is cycloalkyl.
6. R1 is t-butyl, R2 is H, and R4 is OCF 3 , O.C.H. 2 CF 3 , O.C.H.F. 2 , or C.F. 3 The pharmaceutical composition according to any one of claims 1 to 5,
7. R1 and R2 join to form a cyclobutyl optionally substituted with 1 or 2 F, and R4 is OCF 3 , O.C.H. 2 CF 3 , O.C.H.F. 2 , or C.F. 3 The pharmaceutical composition according to any one of claims 1 to 6,
8. The compound is (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)—N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (R)—N-((S)-1-(3-(difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide, (S)-3-Hydroxy-4,4-dimthyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethyl)phenyl)ethyl)pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)propyl)pentanamide, (S)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)pentanamide, (S)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)propanamide, (R)-3-(1-(difluoromethyl)cyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)propanamide, (R)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(1-(trifluoromethyl)cyclopropyl)propanamide, (S)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-hydroxy-4-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(R)-hydroxy-4,4-dimethylpentanamide, N-((R)-2-(difluoromethoxy)-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-(S)-hydroxy-4,4-dimethylpentanamide, (S)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (R)-3-hydroxy-N-((R)-2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)-4,4-dimethylpentanamide, (S)-2-(3,3-difluoro-1-hydroxycyclobutyl)-N-(1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (S)-2-(1-hydroxycyclobutyl)-N-(1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)acetamide, (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide, 4,4,4-trifluoro-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(trifluoromethyl)butanamide, (R)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (S)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)pentanamide, (R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoromethoxy)phenyl)ethyl)butanamide, (S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-((S)-1-(3-(trifluoro-methoxy)phenyl)ethyl)butanamide, (R)-2-(1-hydroxycyclopentyl)-N-(2-methoxy-1-(3-(trifluoromethoxy)phenyl)ethyl)acetamide, (R)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (S)-3-cyclopropyl-3-hydroxy-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, (R)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide, and (S)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl)butanamide 2. The pharmaceutical composition of claim 1, which is a compound selected from the group consisting of:
9. 9. The pharmaceutical composition according to any one of claims 1 to 8, for the treatment of focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, severe myoclonic epilepsy in infancy, epilepsy with persistent spike-and-wave during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome, or early myoclonic encephalopathy-Ohtahara syndrome, or epileptic seizures associated with stress, hormonal changes, drugs, alcohol, infections, traumatic brain injury, stroke, brain cancer, autism spectrum disorder or metabolic disorders.
10. A pharmaceutical composition described in any one of claims 1 to 8 for the treatment of epileptic symptoms as part of a neurodegenerative disorder.
11. A compound of formula I for the manufacture of a medicament for treating epilepsy, an epilepsy syndrome, an epileptic condition, treatment-resistant or refractory epilepsy, or an epileptic seizure. 【Chemistry 2】 (In the formula, R1 is C 1 ~C 6 Alkyl, CF 3 , C.H. 2 CF 3 , C.F. 2 CHF 2 , C 3 ~C 8 cycloalkyl, wherein said C 3 ~C 8 Cycloalkyl is one or two F, CHF 2 Or CF 3 and R2 is H, C 1 ~C 6 Alkyl or CF 3 or Or, R1 and R2 are bonded to each other to form one or two F, CHF 2 Or CF 3 C optionally substituted with 3 ~C 5 Forming a cycloalkyl, R3 is C 1 ~C 3 Alkyl or CH 2 O-C 1~3 alkyl, 1 ~C 3 Alkyl or CH 2 O-C 1~3 The alkyl may be optionally substituted with one or two F. R4 is OCF 3 , O.C.H. 2 CF 3 or OCHF 2 (selected from the group consisting of or a pharma- ceutical composition comprising the compound of formula (I) or a pharma- ceutical acceptable salt thereof, The use, wherein the pharmaceutical composition further comprises a pharma- ceutically acceptable excipient.
12. 12. The use according to claim 11 for the manufacture of a medicament for treating focal (partial) epilepsy with simple partial seizures, focal (partial) epilepsy with complex partial seizures, idiopathic generalized epilepsy, grand mal epilepsy, status epilepticus, neonatal seizures, KCNQ epileptic encephalopathy (KCNQ2EE) and benign familial neonatal convulsions, severe myoclonic epilepsy of infancy, epilepsy with persistent spike-and-wave during slow wave sleep, West syndrome, Lennox-Gastaut syndrome, Dravet syndrome, or early myoclonic encephalopathy Otahara syndrome, or for the treatment of an epileptic condition as part of a neurodegenerative disorder.
13. The pharmaceutical composition of claim 9, wherein the metabolic disorder is hyponatremia.
14. The pharmaceutical composition of claim 10, wherein the neurodegenerative disorder is Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, or frontotemporal lobar degeneration.
15. The use described in claim 12, wherein the neurodegenerative disorder is Alzheimer's disease, Lewy body disease, juvenile Huntington's disease, or frontotemporal lobar degeneration.
Citation Information
Patent Citations
Novel applications of potassium channel openers
JP2003503447A
Novel quinazoline derivatives and their medical uses
JP2009515934A
Stable form of N-(2,6-dimethyl-4-morpholine-4-ylphenyl)-3,3-dimethylbutylamide
JP2012526152A
Alcohol derivatives as Kv7 potassium channel openers
JP2021519814A
Cited By
Alcohol derivatives as KV7 potassium channel openers
JP2022543203A
Alcohol derivatives as kv7 potassium channel openers
JP2025160211A
